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Abbreviations 
 
SCI Spinal Cord Injury 
CNS Central Nervous System 
CNPSCI Chronic Neuropathic Pain secondary to Spinal Cord Injury
IASP International Association for the Study of Pain 
ISCIPBDS International Spinal Cord Injury Pain Basic Data Set 
NLI Neurological Level of Injury 
DRG Dorsal Root Ganglion 
PAG Periaqueductal Gray 
RVM Rostral Ventral Medulla 
SP Substance P 
CGRP Calcitonin Gene-related Peptide 
SMC Smooth Muscle Cell 
ALT Anterolateral Tract 
GABA Gamma Aminobutyric Acid 
GAD Glutamate Decarboxylase 
NPY Neuropeptide Y 
PAF Primary Afferent Neuron 
NGF Nerve Growth Factor 
BDNF Brain Derived Neurotrophic Factor 
VGSC Voltage Gated Sodium Channel 
VGCC Voltage Gated Calcium Channel 
NMDA receptor N-methyl-D-aspartate receptor 
CCK Cholecystokinin 
TNFα Tumor Necrosis Factor Alpha 
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OECs Olfactory Enscheathing Cells 
MSCs Mesenchymal Stem Cells 
FSCs Fetal Stem Cells 
iPSCs Induced Pluripotent Stem Cells 
PID Post Injury Day 
MGE Media Ganglionic Eminence 
LGE Lateral Ganglionic Eminence 
POA Preoptic Area 
RA Retinoic Acid 
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1. Introduction 
As a worldwide disease, spinal cord injury (SCI) is associated with an annual morbidity 
of 15-40 cases per million population, including approximately 45% of complete SCIs 
(Sekhon and Fehlings 2001). According to the latest report by the US National Spinal 
Cord Injury Statistical Center, SCI frequently occurs at the age group of 16-30 years 
(mean 33.3 years); typically, 81% cases are found in men(French, Campbell et al. 2007). 
SCI is a devastating neurological condition, which generally results in marked loss of 
motor function and feeling below the injury level, as well as chronic pain in most 
patients. About 70% SCI patients have suffered from chronic pain (Stormer, Gerner et al. 
1997, Siddall and Loeser 2001), which can lead to a severe cognitive problems and 
decrease in the quality of life of the patients. Moreover, SCI would also cause great 
burdens on both the families and the society (Westgren and Levi 1998, Andresen, 
Biering-Sorensen et al. 2016). Unfortunately, no totally successful treatment is available 
at present, and there are still many limitations regarding drug therapies, interventional 
measures or other treatments (such as acupuncture) (Chong and Bajwa 2003, O'Connor 
and Dworkin 2009, Magrinelli, Zanette et al. 2013). 
Therefore, the current study aimed to explore the effect of post-SCI GABAergic stem 
cell transplantation on relieving the chronic neuropathic pain after SCI. 
 
1.1. Neuropathic Pain after SCI 
According to the International Association for the Study of Pain (IASP), neuropathic 
pain is defined as a somatosensory nervous system disorder (Treede, Jensen et al. 2008), 
which can be caused by neural damage or disease. Neuropathic pain, which is generally 
chronic and refractory, is associated with the morbidity of 7%-8% of the population 
(Jensen, Gottrup et al. 2001, Torrance, Smith et al. 2006, Bouhassira, Lanteri-Minet et al. 
2008, Gilron, Baron et al. 2015).  
Neuropathic pain displays numerous clinical symptoms, including trigeminal neuralgia 
and herpetic zoster neuralgia. Moreover, neuropathic pain can be induced by a variety of 
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factors; for instance, metabolic problems, vascular disease, injury and infection can give 
rise to peripheral neuropathic pain. In contrast, spinal cord injury (SCI), cancer and 
multiple sclerosis are the leading causes of central neuropathic pain (Jones, Lawson et al. 
2016). Typically, around 40% of the patients would suffer from neuropathic pain after 
chronic SCI (Werhagen, Budh et al. 2004), which will reduce the quality of life of SCI 
patients (Jensen, Chodroff et al. 2007). Specifically, the   neuropathic pain at the 
levelof injury shows up probably earlier than the pain below the level of injury and it 
cannot be alleviated with time (Siddall, McClelland et al. 2003). The clinical 
manifestations of chronic neuropathic pain secondary to spinal cord injury (CNPSCI) 
are hyperalgesia and allodynia, which often manifest as burning, shooting or pricking 
sensations(Finnerup, Johannesen et al. 2001). Meanwhile, there may be fracture, spinal 
nerve compression or injury of the soft tissue after SCI. Thus, the pain may also be 
different (Cardenas and Felix 2009). According to the International Spinal Cord Injury 
Pain Basic Data Set (ISCIPBDS), pain after SCI can be classified into musculoskeletal 
(nociceptive), viscereal (nociceptive), other (nociceptive), at-level SCI (neuropathic), 
below-level SCI (neuropathic), other (neuropathic), other and unknown 
(Widerstrom-Noga, Biering-Sorensen et al. 2008, Cardenas and Felix 2009, 
Widerstrom-Noga, Biering-Sorensen et al. 2014). 
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Table 1. Classification of pain after SCI (Widerstrom-Noga, Biering-Sorensen et al. 
2014) 
 
 
 
1.2. Anatomical physiology of neuropathic pain 
1.2.1. Nociceptors 
Nociceptors are the subpopulations of peripheral afferent nerve fibers, which can detect 
the thermal , as well as mechanical and chemical stimuli reaching the noxious range. 
Specifically, the dorsal root ganglia (DRG) connected to the spinal cord are the cell 
bodies of nociceptors, which can conduct the pain signals from the whole body except 
for the face. Besides, the trigeminal ganglia are also the cell bodies of nociceptors, 
which can conduct the pain signals from the face. There are two types of nociceptors, 
including the myelinated fibers and the unmyelinated fibers  (Light and Perl 1979). Of 
them, the myelinated fibers include Aδ (responding to touch or hair movement) and Aβ 
Musculoskeletal (nociceptive) Pain originating in the musculoskeletal structures. 
Visceral (nociceptive) Pain locating in the thorax, abdomen or pelvis and 
originating in visceral structures. 
Other (nociceptive) Nociceptive pain that is not classified into 
musculoskeletal or visceral pains. 
At-level SCI (neuropathic) Pain located within or at three dermatomes below 
the neurological level of injury (NLI) 
Below-level SCI (neuropathic) Pain locating at three dermatomes below the NLI. 
Other (neuropathic) Neuropathic pain locating above, at, or below the 
NLI but not directly related to SCI. 
Other Pain unrelated to SCI and no induced by any 
identifiable noxious stimulus, inflammation or 
damage to the nervous system. 
Unknown Pain of unknown etiology. 
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fibers (low-threshold mechanoreceptors). These fibers, which have large diameters, can 
conduct signals at a very fast speed and are mainly associated with the fast pain or “first 
pain”. On the other hand, the unmyelinated fibers include C fibers with a small diameter 
(0.2-1.5μm) and slow signal conduction speed. Therefore, they are related to the slow 
pain or “second pain” (Basbaum, Bautista et al. 2009, Todd 2010, Lewin and Nykjaer 
2014, Benarroch 2016). Meanwhile, C fibers can also be divided into two groups, 
namely, non-peptidergic fibers (related to the skin) and peptidergic fibers (related to 
other tissues and the deeper regions of the skin) (Plenderleith and Snow 1993, Taylor, 
Peleshok et al. 2009).  
The noxious pain signal generated by nociceptors will pass through the laminae I and 
laminae V, pass through the thalamus or amygdala, and reach the cerebral cortex. The 
somatosensory cortex can then detect the location and intensity of pain, and the pain 
signal will later cause emotional changes after it is conducted to the cingulate cortex and 
insular cortex (Yalcin, Barthas et al. 2014). Afterwards, the pain sensation can be 
generated under the cooperation of the cerebral cortex, thalamus and limbic system. 
Notably, both periaqueductal gray (PAG) and rostral ventral medulla (RVM) play vital 
roles in the descending pathways (Chuquilin, Alghalith et al. 2016).  
At the same time, there is also another classification of nociceptors into thermal, 
mechanical and chemical nociceptors depending on the types of stimulus. Amongst 
them, thermal nociceptors can be activated by a heat or cold stimulus. The 
thermo-transient receptor potential channels (Thermo-TRP channels), which have over 
6 subtypes, are related to this pain process. Typically, temperature higher than 43°C can 
activate TRPV1, which can also detect the chemical noxious stimulus (Khomula, 
Viatchenko-Karpinski et al. 2013, Labuz, Spahn et al. 2016, Nozadze, Tsiklauri et al. 
2016); whereas TRPM8 is related to the cold sensation (Dhaka, Earley et al. 2008, Liu 
and Jordt 2018). Besides, mechanical nociceptors respond to mechanical stimuli, among 
which, TRPA1 is involved in this mechanical nociception mechanism (Fischer, Tambeli 
et al. 2008, Nozadze, Tsiklauri et al. 2016).  
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Furthermore, nociceptors also take part in the inflammatory and immune processes to 
regulate the pain, which is achieved through releasing neuropeptides and 
neurotransmitters from the peripheral terminals. Concretely, both calcitonin gene-related 
peptide (CGRP) and Substance P (SP) are released in the peripheral nerve terminals in 
the presence of calcium influx, which is induced by the noxious signal. Of them, CGRP 
contributes to muscle relaxation and vasodilation through activation of the 
RAMP1/CalcRL receptor in vascular smooth muscle cells (VSMCs). In addition, it can 
also enhance IL17 production by Th17 Cells and γδT cells in the psoriasis-like 
inflammation. In contrast, SP can activate tachykinin receptor 1 and 2 (TACR1/2) in 
vascular endothelial cells (VECs), which can thereby increase the vascular permeability, 
resulting in edema formation.(Pinho-Ribeiro, Verri et al. 2017) 
 
1.2.2. Functions of interneurons in the dorsal horn circuits 
There are two main types of dorsal horn neurons, including projection cells that have 
axons to project signals to the brain, and interneurons whose axons remain in the spinal 
cord. The pain-related projection neurons mostly belong to the anterolateral tract (ALT), 
and most ALT projection cells are in lamina I, while few of them are in lamina III – VI. 
They can project pain signals to the thalamus (through the spino-thalamic tract), 
reticular formation (through spino-reticular fibers) and to the periaqueductal grey matter 
of the midbrain. Moreover, interneurons can be mainly categorized into two types, 
namely, the inhibitory interneurons and excitatory interneurons. Of them, the inhibitory 
interneurons can utilize the GABA or glycine as a transmitter (Todd and Sullivan 1990). 
The GABAergic interneurons are shown to distribute in the laminae I-III through 
immunocytochemistry using GABA antibodies and the GABA synthesized enzyme 
glutamate decarboxylase (GAD) (Mitchell, Gentet et al. 2007, Polgar, Durrieux et al. 
2013). Alternatively, the distribution of inhibitory interneurons in the spinal cord can 
also be defined using Pax2 and Lmx1b (Kardon, Polgar et al. 2014, Foster, Wildner et al. 
2015, Gutierrez-Mecinas, Bell et al. 2017). Importantly, inhibitory interneurons, which 
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can release various neuropeptides (such as for nociception: neuropeptide Y (NPY), 
opioid peptides: enkephalin, dynorphin and galanin(Rowan, Todd et al. 1993, Duan, 
Cheng et al. 2014)), are shown to play a critical role in maintaining the balance between 
excitation and inhibition. 
The dorsal horn gray matter in the spinal cord is separated into ten layers. Among them, 
Lamina I-X are surrounded by white matter (Rexed 1952), but only Lamina I-VI are 
related to neuropathic pain. Moreover, Lamina I-VI consist of the posteriordorsal horn, 
while Lamina I-III can collect most of the nociceptive afferent signals (Fig.1)(Todd 
2010). Lamina I, where the Aδ nociceptor signal passes through (Dhaka, Earley et al. 
2008), is the margin of the gray matter consisting of the marginal nucleus of spinal cord. 
Most neurons in this layer are related to the noxious and innocuous stimuli, and some 
neurons can specifically receive the noxious stimuli. Lamina II, also called substantia 
gelatinosa of Rolando, is the layer below Lamina I, which contains small interneurons 
and unmyelinated fibers to conduct the slow pain signal. To be specific, mechanical C 
fibers mainly conduct signals into this lamina(Liu, Vrontou et al. 2007, Seal, Wang et al. 
2009). Lamina I and Lamina II are both the outer layer that is called superficial dorsal 
horn. There are more myelinated fibers in Lamina III, but the interneurons in this layer 
can only conduct the innocuous mechanical stimuli. Lamina IV is similar to Lamina III, 
but is thicker and can receive the innocuous stimuli together with Lamina III. These two 
layers are comprised of the nucleus proprius. Notably, Lamina V is the widest layer, 
where interneurons can conduct the pain signal to the brain stem, thalamus and 
cerebellum. Besides, Lamina III-V can collect both the noxious and innocuous stimulus 
signal from the Aβ fibers. Finally, Lamina VI is the base of the dorsal horn, which 
contributes to the fast pain flexion reflex(Todd 2010, von Hehn, Baron et al. 2012, Duan, 
Cheng et al. 2014, Benarroch 2016). 
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Fig.1. Dorsal horn and primary afferent inputs (Benarroch 2016). 
 
1.2.3. Peripheral mechanisms of neuropathic pain 
The peripheral mechanism is mainly about the decreased pain threshold and increased 
excitability of nociceptors. On this basis, innocuous stimuli can cause a painful 
sensation called allodynia. Alternatively, a normally slight pain feeling aggravates to an 
extremely pain that is referred to as hyperalgesia.(Treede, Meyer et al. 1992). Both of 
them may take place after injury of the primary afferent neurons (PAF). Typically, there 
exist many different theories about this peripheral sensitization. (Millan 1999, Ito, 
Okuda-Ashitaka et al. 2001, Sommer and Kress 2004). 
Damage of the nerve fibers will lead to a local inflammatory reaction. As a result, the 
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“inflammation soup” can be released from the nociceptors or other cell types, which is 
comprised of histamine, bradykinin, neurotrophins, adenosine triphosphate, serotonin, 
nerve growth factor (NGF), cytokines (IL-1 ß, TNF-α, IL-6), calcitonin-gene related 
peptide (CGRP), substance P (SP) and brain-derived neurotrophic factor (BDNF). These 
factors can infiltrate into the injured area, which facilitate the vasodilatation and 
regulate the inflammatory response in mast cells, basophils, macrophages, neutrophils, 
endothelial cells and fibroblasts. Moreover, they may also increase the sensitivity of 
neurons to nociceptor stimuli (Willis and Westlund 1997, Millan 1999, Ito, 
Okuda-Ashitaka et al. 2001, Sommer and Kress 2004). 
Besides, the sympathetic nervous system may also be involved in the formation of 
neuropathic pain. After PAF injury, the sympathetic axons in PAF and DRG areas can 
form the baskets around the sensory neurons, which will increase the ectopic activity of 
the DRG cells (Devor, Wall et al. 1992, Amir and Devor 1993, McLachlan, Janig et al. 
1993). 
Concretely, changes in the ion channels may be mainly responsible for the neuropathic 
pain after PAF injury. During this process, the voltage-gated sodium channels (VGSCs) 
and voltage-gated calcium channels (VGCCs) are both enhanced, which have played 
key roles in releasing neurotransmitters from the nociceptors (Field, Hughes et al. 2000, 
Altier and Zamponi 2004). Besides, there are also great changes in the sodium channels; 
for instance, the expression of Nav 1.3 in the dorsal horn and nociceptive neurons is 
up-regulated. Meanwhile, Nav 1.8 expression is also up-regulated, which plays a vital 
role in changing the threshold and forming hyperalgesia. Additionally, other sodium 
channels are also involved in forming neuropathic pain (Hains, Klein et al. 2003, Wood, 
Boorman et al. 2004, Luiz and Wood 2016), which together with some potassium 
channels and calcium channels, have exerted some functions in processing neuropathic 
pain. Typically, the non-selective cation channel TRPV1, which is vital in the 
inflammatory pain, is altered after nerve injury. Besides, TRPV1 is up-regulated in the 
uninjured sensory fibers (Hudson, Bevan et al. 2001, Huang, Zhang et al. 2006, 
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Khomula, Viatchenko-Karpinski et al. 2013, Orestes, Osuru et al. 2013, Yamamoto, 
Suzuki et al. 2016, Leo, Schmitt et al. 2017). Simultaneously, other ion channels, like 
TRPA1, TRPM8 or P2X3, are also partially changed after nerve injury, but whether they 
can cause neuropathic pain remains unclear so far (Shinoda, Kawashima et al. 2007, Eid, 
Crown et al. 2008, Xu, Li et al. 2011). 
 
1.2.4. Central sensitization mechanisms of neuropathic pain 
Central sensitization is the process that amplifies the incoming signals within the central 
nervous system (CNS), which can form a long lasting synaptic plasticity from a burst 
activity of the nociceptors. Moreover, it can also amplify signals from the primary 
afferents to induce the more severely intensive reaction in postsynaptic neurons known 
as the hyperalgesia. Through this central sensitization process Typically, both the C 
fibers and Aβ fibers signals can be amplified through this central sensitization process 
(Ikoma, Fartasch et al. 2004, Baron, Binder et al. 2010, Ploner, Lee et al. 2011). 
Three main mechanisms are involved in the central sensitization process, including 
glutamatergic neurotransmission alteration (N-methyl-D-aspartate receptor (NMDA 
receptor)-mediated hypersensitivity), loss of GABAergic or glycinergic inhibition, and 
neuroglia interactions (Basbaum, Bautista et al. 2009). 
Usually, the glutamate receptor cannot be activated only through glutamate binding as a 
result of the Mg2+ blocking of the receptor. However, after the persistent stimulation of 
peripheral noxious stimulus, the released glutamate participates in the postsynaptic 
reaction of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA 
receptor), which opens the Na+ and Ca2+ channels, rendering the influx of Na+ and 
Ca2+ and creating the rapid excitatory postsynaptic potentials. These potentials will 
thereby trigger the VGCCs and lead to a higher level of depolarization (Dickenson, 
Chapman et al. 1997, Collins, Sigtermans et al. 2010). Finally, the continuous 
accumulation of depolarization can remove the Mg2+ blocking of the NMDA receptor, 
so that it can be activated by glutamate binding. This will also result in cell 
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depolarization and induce Ca2+ influx, which will thereby enhance signal conduction 
from nociceptors to spinal dorsal neurons, thus leading to the hyperalgesia reaction . 
Increases in excitatory postsynaptic potential and neuronal excitability play a crucial 
part in neuropathic pain; nonetheless, the loss of dorsal horn inhibition is also very 
important. To be specific, the inhibitory gamma-amino-butyric-acid (GABA) and 
glycinergic interneurons in the superficial layers of the dorsal horn can be activated by 
the nociceptive pain signals, which can thus generate the inhibitory impulse to maintain 
the inhibition state. GABA, the major inhibitory neurotransmitter in the superficial layer 
of the dorsal horn, is constituted by GABAA-receptors and GABAB-receptors. Of them, 
GABAA-receptors serve as the ligand-gated chloride channels(Bhisitkul, Kocsis et al. 
1990), which allow the chloride ions to get into cells when activated and lead to 
inhibitory function. In contrast, GABAB-receptors are the G protein-coupled receptors 
(GPCRs), which can inhibit the release of both glutamate and SP. Peripheral nerve 
injury can cause the decrease in GABA-induced inhibitory function due to the loss of 
GABAergic interneurons in the dorsal horn(Moore, Kohno et al. 2002, Janssen, Truin et 
al. 2011, Benarroch 2016). Notably, bicuculline, a GABAA-receptor antagonist, is used 
in a pharmacological study to induce neuron hyperexcitability and neuropathic 
pain(Sorkin, Puig et al. 1998). Moreover, another study has promoted the function of 
GABAergic interneurons through the pharmacological method, which can alleviate 
neuropathic pain(Gwak and Hulsebosch 2011). Besides, another important inhibitory 
reaction is related to opioid-receptor, which is also reduced after peripheral nerve injury. 
This will lead to reduced synthesis and release of Cholecystokinin (CCK), which is 
responsible for the opioid inhibitory function(Besse, Lombard et al. 1992). 
After peripheral nerve injury, many microglia and astrocytes will be accumulated 
around the injured area, and the activated microglia can therefore affect the ligand-gated 
ion channel receptors and GPCRs (CB2 or P2U purinoceptors), leading to the increased 
intracellular Ca2+ and activation of p38 MAPK. In addition, many different signal 
molecules will be secreted, such as the cytokines (tumor necrosis factor alpha (TNF-α)), 
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chemokines and trophic factors, which can enhance the sensitization of neuropathic pain 
(Inoue, Tsuda et al. 2005, Tsuda, Inoue et al. 2005, Wieseler-Frank, Maier et al. 2005). 
 
 
Fig.2. Mechanism of mechanical allodynia and itch. The loss of GABA, glycinergic 
or dynorphin inhibition in the dorsal horn. (Benarroch 2016)  
 
 
1.2.5. Stem cell transplantation (SCT) for SCI 
Various types of stem cells have been transplanted into the injured spinal cord; for 
example, olfactory ensheating cells (OECs), mesenchymal stem cells (MSCs), fetal 
stem cells (FSCs), and induced pluripotent stem cells (iPSCs). Specifically, OECs were 
first transplanted by Ramon and Nieto in 1994 (Ramon-Cueto and Nieto-Sampedro 
1994). OECs can generate nerve regeneration since they have the functions of astrocytes 
and Schwann cells (Choi and Gladwin 2015). Great outcomes have been attained after 
transplantation, as shown in many animal studies. Also, some clinical trials have 
suggested recovery below the injury level (Tabakow, Raisman et al. 2014). However, 
the culture and transplantation techniques for OECs remain a source of controversy 
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(Novikova, Lobov et al. 2011). MSCs are the multipotent stromal cells that can 
differentiate into osteoblasts, chondrocytes and adipocytes under different culture 
conditions. In addition, MSCs are shown in a study to differentiate into nerve tissue 
(Deans and Moseley 2000). Noteworthily, many experiments have verified the benefits 
of MSCs transplantation for SCI animals(Dasari, Veeravalli et al. 2014). FSCs are 
collected from the embryos, which can differentiate into neurons, astrocytes and 
oligodendrocytes. FSCs transplantation has been confirmed in studies to alleviate 
neuropathic pain or even contribute to the regrowth of the injured nerve fibers; however, 
the underlying mechanisms remains unclear so far (Kadoya, Lu et al. 2016). Takahashi 
and Yamanaka had found a way to recover the pluripotency from human 
fibroblasts(Takahashi and Yamanaka 2006). Nowadays, iPSCs can be produced from 
many different cells in different ways. In some studies, iPSCs are transplanted into the 
SCI mouse model, which achieve motor function recovery after transplantation 
(Kobayashi, Okada et al. 2012).  
The current study aims to transplant neural stem cells (NSCs) isolated from the rat 
embryos, but the interventional management is still challenging (Dworkin, O'Connor et 
al. 2013), and the underlying pathophysiology remains unknown. More recently, 
dendritic spine remodelling on the second-order wide dynamic range neurons in dorsal 
horn (Tan and Waxman 2012), synaptogenesis, dendritic sprouting, astrocytes activation 
(Gwak, Kang et al. 2012), and even dysregulation of potassium channels (Kv3.4) in 
DRG have been found to be implicated (Ritter, Zemel et al. 2015). Moreover, the main 
hypothesis of CNPSCI is changed in receptor function and increased neuronal 
excitability caused by the loss of inhibitory interneurons. Additionally, it is well known 
that a lesion at any level in both central nervous system (CNS) and peripheral nervous 
system (PNS) can lead to changes in the descending inhibitory circuits, while GABA is 
the inhibitory neurotransmitter that plays an important role in CNPSCI (Sivilotti and 
Woolf 1994, Gwak, Tan et al. 2006, Jiang, Fuller et al. 2016). An electrophysiological 
research has confirmed the deficits of GABAergic inhibitory neurotransmitters in 
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CNPSCI (Moore, Kohno et al. 2002). The application of GABA antagonists can lead to 
hypersensitivity to non-injurious tactile stimuli (Hao, Xu et al. 1994). Moreover, clinical 
observations have shown that patients with pain after SCI can respond well to 
GABA-agonists, and some of them are rated as level A in terms of their efficacy against 
such central pain(Attal, Cruccu et al. 2010). 
 
1.3. Aims of the study 
 We wanted to generate neuropathic pain by establishing a hemisection 
trauma model in the rat. 
 It was our hypothesis that the transplantation of GABAergic 
neuroprogenitor cells into the spinal dorsal horn may alleviate neuropathic 
pain. 
 
 
2. Materials and Methods 
2.1. Animal model of neuropathic pain 
All animal procedures were approved by the Ethics Committee for Animal Research in 
the State of Baden-Württemberg (Regierungspräsidium Stuttgart), under the protocol 
number of C5/12. 
35 male Sprague-Dawley (SD) rats weighing 240-260g were housed under standard 
conditions with free access to both food and water, and kept on a 12h/12h dark/light 
cycle. All rats underwent lateral dorsal hemisection at T13 level with the cutting depth 
of 1 mm. 
 
2.2. Surgical procedure 
All surgeries were performed in a sterile operating room. The rats were intraperitoneally 
injected with a mixture of ketamine (Ketaset, 7-10mg/100g bodyweight; Parke Davis, 
Germany) and xylazine (Rompun 1mg/100g bodyweight; Bayer, Germany) for 
21 
 
 
 
anesthesia. Then they were kept on a heating pad to maintain their body temperature 
intraoperatively. The backs of rats were all shaved before surgery. Later, the T13 
vertebra was identified through palpation of 13th rib. The vertebrae of rats were fixed 
using the forceps of the stereotactic apparatus (Stereotaxic apparatus for rat and mouse, 
SGL M), followed by laminectomy between the T12-13 vertebral segments. Typically, 
the dorsal spinal blood vessels could be spared by using the operating microscope, and 
the dorsal root entry zones could be clearly visualized. Surgery in the sham operation 
group was finished at this step, without inducing any injury to the spinal cord; whereas 
the dorsal spinal cords of rats in the other groups were hemisected, just from the cranial 
to the dorsal root entry zone using a No. 11 scalpel blade. Attention should be paid to 
strictly keep the section depth of 1 mm (Fig.2). Later, muscles and fascia were sutured, 
and the skin was sutured as well. The whole surgical procedure was performed under 
standard sterile conditions. During the first week after surgery, rats were housed 
separately in cages with a thick layer of sawdust and were given analgesics (Metamizole) 
supplemented in water. The motor function was controlled from the first post-injury day 
(PID). 
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Fig.3. Hemisection of T13 spinal cord using the No. 11 surgical blade at the cutting 
depth of 1 mm. 
 
2.3. Isolation of neural progenitor cells (NPCs) 
Embryonic cortical NPCs were isolated from E14 SD rats. Pregnant rats were 
intraperitoneally injected with a mixture of ketamine (Ketaset, 7-10mg/100g 
bodyweight; Parke Davis, Germany) and xylazine (Rompun 1mg/100g bodyweight; 
Bayer, Germany) for deep anesthesia. Afterwards, a midline ventral incision was made 
to expose the embryos. Typically, most GABAergic inhibitory interneurons were 
derived from the ventral telencephalon; to be more accurate, they came from the lateral 
ganglionic eminence (LGE), medial ganglionic eminence (MGE) and the embryonic 
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preoptic area (POA). These embryonic brain tissues were collected under the 
microscope (Fig.3) and placed into a 15 ml conical tube containing cold Hank’s 
balanced salt solution (HBSS; Invitrogen/Gibco). The brain sections were dissected, 
followed by a low-speed centrifuge at 200 g for 1 min at room temperature (20–25 °C). 
The supernatant was removed using the MACS neural tissue dissociation kit (Miltenyi 
Biotec). Then, enzymes were added step by step to each 15 ml conical tube containing 
the tissue bulks. A fire-polished glass pipette was pre-wet to triturate the tissue through 
pipetting up and down for 10–20 times until no tissue bulk was observed. 8 ml N2 
medium was then added into each tube to dilute the enzyme mixture. Subsequently, 
cells were pelleted at 200 g for 5 min at room temperature, and the conical tubes were 
placed onto the MACSmix tube rotator for 20 min of rotation at room temperature. The 
tissues samples were then resuspended and plated in N2 growth media 
(DMEM/F12+N2 supplement, pH7.2; Invitrogen/Gibco) containing the standard 
concentration of FGF-2 (10ng/ml, FGF-2; PeproTech) at 37˚C (Fig.4). 
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Fig.4. Collection of LGE, MGE and POA tissues from the E14 rat embryos. 
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Fig.5. A schematic overview of the major steps in this protocol. 
 
2.4. Differentiation of NPCs 
After 7–14 days of culture (Fig.5), all primary spheres were collected without disturbing 
the attached cells, followed by centrifugation at 200 g for 5 min at room temperature 
and resuspension in N2 medium supplemented with a final concentration of 1 μM 
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Retinoic acid (RA; Sigma-Aldrich) and 1 μM Forskolin (FSK; Sigma-Aldrich). Cells 
were further incubated, and the medium was replaced every day for 4 days continuously. 
All neurospheres were then collected and digested into single cells, and the viable cells 
were counted by trypan blue exclusion.  
 
Fig.6. Culture of NPCs. (A) First day of culture. (B) Four days of culture. (C) Eight 
days of culture (D) Twelve days of culture. All the scale bars were 100um. 
 
2.5. Transplantation of GABAergic NPCs 
Only rats developing mechanical neuropathic pain had received cell transplantation 
(n=15).  The animals were anesthetized and a T13–L1 laminectomy was performed 
aseptically to expose the L3–L4 lumbar spinal cord. Cells were loaded into the 
Hamilton microinjection syringe (PN 65460-06, gauge 33, OD=0.21 mm x ID= 0.11, 
Point style 4 comes with 12º; Hamilton), and injected into the hemi-section side, with 
the syringe being placed 0.5 mm from the dorsal central vein at the injection depth of 
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0.5 mm to 1 mm. Three injections of 4ul NPCs (5×104 cells/µl) were applied to the 
experiment group, while PBS was injected in the control group (n=15), and the injection 
speed was controlled by a micro injection pump at 1µl/min. Afterwards, the syringe was 
left in place for 1 min to prevent cell backflow (Fig.6). Muscles were later sutured 
lay-by-layer to cover the injection site, and the skin was closed with wound clips. All 
rats were placed in some heated cages for recovery after surgery and received 
immunosuppression with cyclosporine A (i.p.,10mg/kg; Bedford Labs, OH, USA) from 
one day prior to transplantation until sacrifice. 
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Fig.7. Transplantation of cells and PBS. 
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2.6. Motor function assessment 
To confirm the preservation of postoperative locomotor function, the Basso, Beattie, and 
Bresnahan (BBB) locomotor rating scale was used (Basso, Beattie et al. 1995). A round 
plastic pool 100 cm in diameter and 17 cm in height was used in our experiment to 
monitor the motor function in rats. Then, the ipsilateral hind limb on the injury side and 
contralateral hind limb were both evaluated from the first day, and weekly after the 
surgery. Moreover, videos of the evaluation were also taken each time. Each rat was 
examined by two examiners at the same time, so as to minimize the observer-related 
bias. The BBB scale, which is sensitive to the animals with mild SCI, is a 
semiquantitative scale with the values ranging from 0 to 21. The scoring depends on the 
following forms (Table 2) regarding the limb movement, trunk position, abdomen, paw 
placement, stepping, coordination, clear toe, predominant paw position, trunk instability 
and tail. The rating scales were shown in Table 3. In the scale table, 0 suggested no 
movement of the hindlimb, whereas 21 indicated full function of plantar stepping, 
coordinated gait, toes movement, trunk stability and tail elevation. 
 
Table 2. BBB locomotor rating sheet. 
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Table 3. BBB locomotor rating scale.(Basso, Beattie et al. 1995) 
 
 
2.7. Pain assessment 
2.7.1. Mechanical pain 
The mechanical thresholds on the plantar surface of the rats were determined using the 
von Frey filaments (Dynamic Plantar Aesthesiometer, Cat. No. 37400-001, Ugo Basile, 
Italy) before and after surgery. Typically, all rats were trained every day for one week 
31 
 
 
 
before surgery. Initially, they were kept in a quiet testing environment for 30 minutes in 
order to adapt to the surrounding, before they were put into a transparent plastic animal 
enclosure over a perforated platform (Cat. No. 37450-278, Ugo Basile, Italy) for another 
20 minutes. To apply the mechanical stimulation, the central part of the hind paw was 
targeted under the guidance of a mirror. Afterwards, a dynamic force ranging from 0 to 
50 grams was applied within a time frame of 20 seconds to the target point through a 
metal filament. Specifically, the force of 50 grams was set as the maximal cut-off force, 
so as to protect the paw from a stab injury. Concretely, the pain threshold of the 
mechanical stimulation was recorded through two different methods, namely, effective 
hind paw withdrawal reflex and other behavioral signs of pain. Both left and right hind 
paws were tested for five times to calculate the mean of the mechanical force, and the 
baseline value for the mechanical threshold was set one day before surgery. 
 
Fig.8. Pain assessment electronic von Frey filaments for quantification of tactile 
sensation (thickly-myelinated fibers) (Ugo Basile, Italy) 
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2.8. Evaluation and statistical analysis 
All data were analyzed using the Graph Pad Prism 7.0 software (Graph-Pad Software 
Inc., San Diego, CA, USA). For all statistical analyses, a difference of P<0.05 was 
estimated as statistically significant. 
 
3. Results 
In this project, the GABAergic precursors are transplanted into the first relay station of 
the pain pathway to inhibit pain transmission, using the dorsal spinal cord hemi-section 
rat model. The rats used in our study are divided into three subgroups, including shame 
operation group, transplanted with culture medium group and transplanted with 
GABAergic precursors group. Each group have 15 rats. 
3.1. Motor function 
After the first day of surgery, the BBB score on the injury side of Sham Operation 
Group was 19.53 ± 1.19 (Fig.8, Table 4), which was almost the same as the normal 
score, suggesting that rats had consistent plantar stepping and consistent coordinated 
gait. Three days later, the BBB score recovered fully to 21. On the first day after 
hemi-section surgery, the BBB score on the injury side of Transplant PBS Group was 
10.867 ± 2.560, which recovered to 18.667 ± 2.610 after the first week, decreased to 
14.867 ± 3.441 after transplantation, and recovered to normal level in the second week 
after transplantation of PBS (Fig.9, Table 5). The BBB score on the injury side of 
Transplantation of Cells Group on the first day of hemi-section surgery was 12.267 ± 
2.052, which resumed to 19.867 ± 1.959 seven days later, revealing a nearly complete 
recovery. This score also indicated the facility of extension movements of all joints, 
bearing of body weight and recovery of coordination between the hindlimbs and 
forelimbs. After cell transplantation, such score decreased to 16.333 ± 2.093, and the 
motor function had markedly recovered. One week later, the motor score was 20.867 ± 
0.516, which indicated the rats had consistent trunk stability and could easily step 
(Fig.10, Table 6). The results of BBB scores among the three groups were compared, as 
33 
 
 
 
shown in Fig.11. Most importantly, no rat showed a sign of bladder or bowel 
dysfunction during the two surgeries. 
 
  
Fig.9. The BBB scores of the sham operation group. The locomotor function of this 
group showed only slight difference within the normal level. The BBB score was 
19.533 ± 1.187 on the first day after sham SCI operation, while that on the first day 
after sham transplantation operation was 19.733 ± 1.280. 
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Table 4. Quantification of BBB Scores in sham operation group. 
 Mean SD N 
Pre SCI 21.000 0.000 15 
D1 after SCI 19.533 1.187 15 
D2 after SCI 20.733 0.458 15 
D3 after SCI 21.000 0.000 15 
D4 after SCI 21.000 0.000 15 
D5 after SCI 21.000 0.000 15 
D6 after SCI 21.000 0.000 15 
D7 after SCI 21.000 0.000 15 
D1 after Trans. 19.733 1.280 15 
D2 after Trans. 20.533 0.743 15 
D3 after Trans. 20.933 0.258 15 
D4 after Trans. 21.000 0.000 15 
D5 after Trans. 21.000 0.000 15 
D6 after Trans. 21.000 0.000 15 
D7 after Trans. 21.000 0.000 15 
W2 after Trans. 21.000 0.000 15 
W3 after Trans. 21.000 0.000 15 
W4 after Trans. 21.000 0.000 15 
W5 after Trans. 21.000 0.000 15 
W6 after Trans. 21.000 0.000 15 
W7 after Trans. 21.000 0.000 15 
W8 after Trans. 21.000 0.000 15 
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Fig.10. The BBB scores in PBS transplantation group. The BBB score was 10.867 ± 
2.560 on the first day after SCI operation, which had recovered to 18.667 ± 2.610 
one week later and was decreased to 14.867 ± 3.441 after transplantation. It had 
recovered to normal level in the second week after transplantation. 
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Table 5. Quantification of BBB Scores in PBS transplantation group. 
 Mean SD N 
Pre SCI 21.000 0.000 15 
D1 after SCI 10.867 2.560 15 
D2 after SCI 10.800 2.145 15 
D3 after SCI 12.400 2.324 15 
D4 after SCI 13.867 2.532 15 
D5 after SCI 15.600 2.823 15 
D6 after SCI 17.667 2.690 15 
D7 after SCI 18.667 2.610 15 
D1 after Trans. 14.867 3.441 15 
D2 after Trans. 15.333 3.039 15 
D3 after Trans. 16.667 3.309 15 
D4 after Trans. 18.067 2.815 15 
D5 after Trans. 19.133 2.416 15 
D6 after Trans. 19.600 1.844 15 
D7 after Trans. 20.400 1.056 15 
W2 after Trans. 21.000 0.000 15 
W3 after Trans. 21.000 0.000 15 
W4 after Trans. 21.000 0.000 15 
W5 after Trans. 21.000 0.000 15 
W6 after Trans. 21.000 0.000 15 
W7 after Trans. 21.000 0.000 15 
W8 after Trans. 21.000 0.000 15 
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Fig.11. BBB scores in cells transplantation group. The BBB score on the injury side 
on the first day of hemi-section surgery was 12.267 ± 2.052, which had resumed to 
19.867 ± 1.959 seven days later and was decreased to 16.333 ± 2.093 after cell 
transplantation. The motor function had markedly recovered after transplantation, 
and the motor score was 20.867 ± 0.516 one week later. 
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Table 6. Quantification of BBB Scores in cells transplantation group. 
 Mean SD N 
Pre SCI 21.000 0.000 15 
D1 after SCI 12.267 2.052 15 
D2 after SCI 12.600 1.805 15 
D3 after SCI 13.933 2.251 15 
D4 after SCI 15.467 2.446 15 
D5 after SCI 16.933 2.434 15 
D6 after SCI 18.400 2.558 15 
D7 after SCI 19.867 1.959 15 
D1 after Trans. 16.333 2.093 15 
D2 after Trans. 17.200 2.178 15 
D3 after Trans. 18.667 2.469 15 
D4 after Trans. 19.867 2.031 15 
D5 after Trans. 20.400 1.549 15 
D6 after Trans. 20.733 0.799 15 
D7 after Trans. 20.867 0.516 15 
W2 after Trans. 21.000 0.000 15 
W3 after Trans. 21.000 0.000 15 
W4 after Trans. 21.000 0.000 15 
W5 after Trans. 21.000 0.000 15 
W6 after Trans. 21.000 0.000 15 
W7 after Trans. 21.000 0.000 15 
W8 after Trans. 21.000 0.000 15 
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Fig.12. BBB Score on the injury (dorsal hemisection) side of the hindlimbs. The 
X-axis indicated the time from the first week after SCI measured in days to the 
first week after transplantation measured in days and then weekly. The motor 
function was recorded daily for one more week. The BBB scores were measured 
weekly one week later until the eighth week. “Pre” indicated before surgery. The 
BBB scores in hindlimbs were 21 before SCI and in W2, W3, W4, W5, W6, W7, 
and W8, suggesting complete recovery of the motor function. 
 
3.2. Mechanical allodynia 
According to the report by Jutatip Guptarak et al., a 23% natural variation of mechanical 
thresholds was observed in naive rats (Sivilotti and Woolf 1994). In our study, the 
threshold of mechanical allodynia was found to be decreased by more than 25% (Fig. 2, 
red and green lines).  
At the assessment one week after SCI, a substantial decrease in the mechanical pain 
threshold of the hindlimb on the injury side was noted in Transplant PBS Group (32.578 
± 2.700 g, Table. 7) and Transplant Cells Group (28.357 ± 1.307 g, Table 6), indicating 
mechanical allodynia. More importantly, during the whole eight-week evaluation period, 
no significant spontaneous recovery of the mechanical pain threshold was observed 
(Fig.15). On the contralateral side, no mechanical allodynia had been observed 
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throughout the whole evaluation period. Typically, the mechanical pain was slightly 
alleviated after GABAergic stem cell transplantation, which remained lower than the 
mechanical allodynia threshold level.  
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Fig.13. Mechanical pain threshold in the sham operation group. The baseline was 
set at 50 g. The mechanical pain thresholds on the injury side hind paw were all 
around 45 g. The quantitative results were shown in Table 7. X-axis was the Time, 
while Y-axis represented the Mechanical Pain Threshold (g). Mean ± SD. 
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Fig.14. Mechanical pain threshold in PBS transplantation group. The baseline was 
set at 50 g. One week after SCI surgery, the mechanical pain threshold on the 
injury side hind paws was decreased to 32.578 ± 2.700, and no substantial change 
was observed during the next several weeks. The quantitative results were 
presented in Table 6. X-axis represented the Time, while Y-axis stood for the 
Mechanical Pain Threshold (g). Mean ± SD. 
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Fig.15. Mechanical pain threshold in cells transplantation group. The baseline was 
set at 50 g. One week after SCI, the mechanical pain threshold was decreased to 
28.357 ± 1.307, which had slightly recovered after transplantation of GABAergic 
progenitor cells. The quantitative results were in Table 6. X-axis was the Time, 
whereas Y-axis indicated the Mechanical Pain Threshold (g). Mean ± SD. 
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Fig.16. Changes in mechanical pain thresholds following hemisection of the dorsal 
column. Notably, mechanical allodynia was established ipsilateral to the lesion side 
as soon as one week after the first operation and one week after transplantation 
until the eighth week. Results of the three groups were presented, including the 
Sham Operation Group (blue), Transplant PBS Group (green) and Transplant 
Cells Group (red). X-axis indicated the Time, while Y-axis suggested the 
Mechanical Pain Threshold (g). Mean ± SD. 
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Table 7. Quantification of Mechanical Behavioral Assays 
 Sham Operation 
Group 
Transplant PBS 
Group 
Transplant Cells 
Group 
Basline 50.000 ± 0.000 50.000 ± 0.000 50.000 ± 0.000 
1W after SCI 45.829 ± 2.006 32.578 ± 2.700 28.357 ± 1.307 
1W after Trans 45.764 ± 1.421 31.322 ± 2.350 28.621 ± 1.897 
2W after Trans 45.414 ± 1.105 31.122 ± 2.509 30.971 ± 1.882 
3W after Trans 45.500 ± 1.269 32.000 ± 2.221 32.014 ± 1.290 
4W after Trans 45.464 ± 1.137 30.922 ± 1.490 33.321 ± 1.418 
5W after Trans 45.607 ± 1.207 30.589 ± 1.574 33.743 ± 1.632 
6W after Trans 45.450 ± 1.219 30.400 ± 2.513 34.450 ± 1.562 
7W after Trans 45.486 ± 0.949 31.404 ± 1.590 34.721 ± 1.876 
8W after Trans 45.807 ± 1.230 30.889 ± 1.456 34.550 ± 1.691 
 
4. Discussion 
4.1. The animal models of neuropathic pain 
Unilateral hemi-section at T13 spinal cord level in rats represents a model of chronic 
SCI, which is characterized by hyperexcitability of posterior horn neurons, the major 
cause of mechanical and thermal allodynia in experimental animals. This animal model 
has been widely used as a model of neuropathic pain, which can be ascribed to its 
numerous advantages, such as controllable amount of the injured spinal cord nerves, 
and less post trauma in hemi-section model than that in spinal contusion animal model. 
Employing this animal model, Hains et al.(Hains, Fullwood et al. 2001, Hains, Johnson 
et al. 2001, Hains, Johnson et al. 2003) suggested that 28 days after trauma, 
hemi-section of spinal cord would result in marked hyperexcitability in a wide range of 
dorsal horn neurons, which were the second order neurons in the afferent pain pathways. 
Typically, the neuropathic pain can last for a long time in this animal model undergoing 
hemi-section(Kim, Yoon et al. 2003). Moreover, many other neuropathic pain models 
45 
 
 
 
have also been used, including (1) the peripheral nerve injury models, like chronic 
constriction injury (CCI), spinal nerve ligation (SNL) and caudal trunk resection; (2) the 
central neuropathic pain models, such as contusive SCI (Allen’s Model), and 
excitotoxic spinal cord injury; (3) the drug-induced neuropathy models, such as 
vincristine-induced neuropathy and cisplatin induced neuropathy; and (4) the 
disease-induced neuropathy models, like peripheral diabetic neuropathy (PDN) and 
cancer pain models. Several SCI models have been proposed before our study, including 
clip compression, direct contusion, hemi-section, and dorsal hemi-section. This study 
mainly aims to analyze the  pain sensation after SCI; as a result, a model that would 
minimally interfere with the efficacy of standard behavioral tests developed for pain 
assessment is required. The spinal cord hemi-section animal model generates stable 
neuropathic pain after SCI, without many other physical dysfunctions, like locomotor 
dysfunction and bladder emptying disorders. According to the motor function of rats in 
our study, all rats after SCI can achieve complete recovery of the motor function. 
Typically, the motor function is slightly decreased after transplantation, but it can also 
recover at a very fast speed. Our previous studies using the clip compression model 
(Lepski, Jannes et al. 2011) suggested that the animals had developed a stable and 
severe motor dysfunction, with no neuropathic pain. The contusion model is an accepted 
and well-established method; however, it may also cause severe and bilateral motor 
deficits, which may potentially interfere with the pain evaluation. This hemi-section 
animal model can closely mimic the myelopathic pain presented by patients after spinal 
cord trauma. Accordingly, the least amount of injury required to produce pain without 
causing significant motor impairment is determined in this study first of all. All rats 
after hemi-section of the dorsal horn have decreased mechanical pain threshold. 
Therefore, the spinal cord hemi-section model seems to be more reliable for the 
generation of neuropathic pain and its later assessment.  
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4.2. Stem cells transplantation after SCI-induced neuropathic pain 
It was previously believed that the central nervous system (CNS) was incapable of 
self-regeneration, as illustrated in an extensive review published by Puchala and 
Windle(Puchala and Windle 1977). These authors had cited the classic animal 
experiments conducted by the Spanish scientist Santiago Ramón y Cajal in the early 
twentieth century, who noted that neurons were indeed able to regenerate. Furthermore, 
he had confirmed that two regenerative processes had taken place following SCI, 
including (1) creation of nerve ending outgrowths by several axons, and (2) the 
formation of collateral outgrowths from the preserved axons in the vicinity of the injury 
in the presence of incomplete spinal transsection. However, none of these processes was 
able to re-establish effective synapses alone, further contributing to the skepticism on 
the regeneration ability of the CNS.   
More recently, a vast body of evidence has shown that potent factors are able to inhibit 
neurite growth in adult CNS, particularly in the white matter. Specifically, both 
oligodendrocyte surface in cell culture and myelin membranes isolated from CNS show 
strong inhibitory effects on neurite outgrowth (Tatagiba, Brosamle et al. 1997). Besides, 
many alternative approaches have been proposed aiming to override the hostile 
environment of white matter in CNS and promote cellular survival as well as axonal 
regeneration in the injured spinal cord. Meanwhile, many other approaches are available, 
including the use of pharmacological agents (Houle and Tessler 2003, Baptiste, Tighe et 
al. 2009), transfection of trophic factor-producing genes (ex vivo gene therapy), or 
transfection of host tissue with a neurotrophic gene, usually through a viral vector (in 
vivo gene therapy) (Kwon and Tetzlaff 2001, Blits, Boer et al. 2002). Initially, the ex 
vivo techniques are based on the implantation of genetically-modified fibroblasts. 
Typically, the neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), 
have emerged as important contributors to the regenerative capacity of CNS neurons, 
rendering them the indispensable components of all successful cellular transplantation 
strategies (Kwon and Tetzlaff 2001). Notably, the importance of BDNF resides in its 
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crucial role in tubulin polymerization during dendritic elongation(Yoo, Joung et al. 
2007), as well as in the generation and maturation of the newly formed synapses (Babu, 
Ramirez-Rodriguez et al. 2009). In this study a further crucial role of BDNF has been 
demonstrated in proper neuronal cell maturation and synapse formation (Babu, 
Ramirez-Rodriguez et al. 2009). Notably, the use of cellular transplantation technique 
has represented another highly promising alternative for overcoming the gliotic barrier 
in the injury site, which may be used to achieve two main goals, namely, (1) 
regeneration to replace the dead or damaged neurons and induce axonal restoration or 
plasticity, and (2) repair, the process in which support cells (such as oligodendrocytes) 
are replaced to promote re-myelination and halt the progressive loss of myelin sheaths. 
Alternatively, cellular transplants can serve to protect endogenous cells from secondary 
injury(Eftekharpour, Karimi-Abdolrezaee et al. 2008). 
 
4.2.1. GABAergic progenitor cells compared with other stem cells 
Many cell types have been transplanted in the neuropathic pain models, such as OECs, 
MSCs, FSCs, and iPSCs. Generally, those cells are derived from several different 
sources, including the internal blastocyst layer (embryonic cells), fetal brain (fetal 
neural cells), mature neuronal tissue (subventricular zone or dentate gyrus of the 
hippocampus), or mature non-neuronal tissues (such as bone marrow) (Dasari, Spomar 
et al. 2007, Conrad, Renninger et al. 2008). Among them, OECs are believed to provide 
the neurotrophic support through a substrate that can facilitate cellular growth and 
remyelination in axons spared from injury(Kwon and Tetzlaff 2001). On the other hand, 
MSCs are abundant even in adult animals, which can be easily obtained from humans 
by simple iliac crest puncture. These cells are biologically safe, and can eliminate the 
need for immunosuppression. Typically, MSCs have been suggested to be capable of 
neuronal differentiation or trans-differentiation(Brazelton, Rossi et al. 2000, 
Sanchez-Ramos, Song et al. 2000, Mezey, Key et al. 2003). Nevertheless, our previous 
study suggested that, although MSCs had acquired the morphological and functional 
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features of neurons, they failed to reach the same maturation stage achieved by neural 
stem cells derived from human or murine fetuses(Lepski 2012). Unfortunately, such 
limitation in MSC differentiation remains largely unknown. Based on our previous 
experience as well as other reports, the role of host microenvironment in proper graft 
survival and differentiation can not be under-emphasized(Lepski, Jannes et al. 2010). Lu 
[31] had transplanted MSCs into a chronic SCI rat model, and found that they were 
genetically modified to express neurotrophin-3 (NT-3), which had given rise to a greater 
stimulation for axonal growth. However, these strategies would not lead to functional 
recovery after chronic SCI, indicating that the regenerated axons fail to form the 
appropriate synapses in the host tissue. Meanwhile, NPCs transfected with Green 
Fluorescent Protein (GFP) are known to be capable of synaptogenesis when implanted 
into the hippocampus of adult rats, and the newly formed synapses are predominantly 
GABAergic. Some researchers also use adult NSCs, which are the tissue-specific 
somatic cells locating in the periventricular regions and the hippocampal dentate gyrus. 
NSCs can differentiate into all types of neuronal cells under specific conditions. 
Specifically, subventricular adult NSCs have been demonstrated in previous work to 
differentiate into three main types of nerve cells, including neurons, oligodendrocytes 
and astrocytes(Kim, Auerbach et al. 2002). Additionally, the functional motor recovery 
has also been demonstrated following transplantation of adult NSCs after pyramidal 
cortex injury in mice (Lepski, Jannes et al. 2010). Interestingly, our previous studies had 
observed a strong tendency for the generation of GABAergic neuronal cells from NSCs 
in a conventional process of differentiation in vitro(Maciaczyk, Singec et al. 2008). 
GABAergic cells are excitatory during the initial phase of development, which can be 
attributable to the absence of a chloride and potassium co-transporter. Later, during the 
maturation process, GABA becomes inhibitory(Ge, Goh et al. 2006). Our studies have 
determined that, around 60% mature neuronal cells obtained from the differentiation of 
NSCs in vitro have assumed the GABAergic phenotype(Maciaczyk, Singec et al. 2008). 
At the same time, changes in GABA expression after SCI or peripheral nerve injury 
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would lead to inhibitory dysfunction, as mentioned in several studies (Polgar, Gray et al. 
2004, Meisner, Marsh et al. 2010). In view of this finding, a hypothesis has been 
proposed, which is that GABAergic precursor cells may ultimately cause post-synaptic 
inhibitory potentials, thus reverting the hyper-excitability that develops in the posterior 
horn neurons after SCI. Therefore, the GABAergic NPCs isolated from MGE of E14 
embryo rats are used in this study, with an aim to study the GABA inhibitory function in 
neuropathic pain after SCI. More GABA or GABAergic cells will be differentiated after 
transplantation of GABAergic NPCs in the injured area, which will enhance the 
inhibitory function. Concretely, some studies have been carried out on increasing 
GABA production to amplify its anticonvulsant effects in epilepsy animal 
models(Handreck, Backofen-Wehrhahn et al. 2014). 
 
4.2.2. Hypothesis of GABAergic NPCs transplantation in alleviating neuropathic 
pain after SCI 
To recover the inhibitory function of the GABAergic neurotransmitters after SCI, we 
have transplanted the GABAergic NPCs into the injured spinal cord. Our results suggest 
that the mechanical threshold is increased one week after transplantation, and has 
recovered till the end of experiment. Moreover, similar studies have also been carried 
out. For instance, Mukhida(Mukhida, Mendez et al. 2007) transplanted the mouse 
striatum GABAergic cells into the neuropathic pain animal models induced by spinal 
nerve ligation. Moreover, Hendricks(Hendricks, Pak et al. 2006) and Kim(Kim, Jung et 
al. 2010) had transplanted embryonic stem cells to reduce the SCI-induced neuropathic 
pain. Additionally, there are various hypotheses regarding the alleviation of neuropathic 
pain. One of the most popular theory is, that GABA secretion is increased after 
transplantation. Typically, there are two main points about this theory, which are, that 
grafted cells can differentiate more GABAergic interneurons(Stubley, Martinez et al. 
2001), or they may reduce cell death by releasing trophic factors in order to generate the 
neuroprotective action (Hollrigel, Toth et al. 1996, Jolkkonen, Halonen et al. 1996). 
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Besides, some researchers have also mentioned the restoration of the spinal serotonergic 
system, which can inhibit the pain transmission(Bowker, Westlund et al. 1981, Marlier, 
Sandillon et al. 1991, Sanchez, Niedbala et al. 1995). The transplanted stem cells can 
alleviate the neuropathic pain, which may possibly be ascribed to the decreased 
hyperexcitability in the dorsal horn, as reported by recording the wind-up phenomenon 
on several studies(Eide, Jorum et al. 1996, Felsby, Nielsen et al. 1996, Sokal and 
Chapman 2001). Moreover, it has been found in electrophysiological studies that, the 
post discharge rate is reduced after NPCs transplantation(Drew, Siddall et al. 2004). 
 
4.3. Limitations of the current study 
In this study, only the mechanical pain is recorded, which is just one part of the 
neuropathic pain. Moreover, the thermo-pain threshold should also be monitored to get 
more proof, and the post-transplant histology is also required in order to detect the 
transplant survival and cell migration, which will be completed by my colleague. 
 
5. Summary  
5.1. Summary 
Spinal cord injury (SCI) is a leading cause of permanent disability and chronic pain, 
which is well-known to induce hyper-excitability in a wide range of neurons in the 
posterior horn of the spinal cord. In turn, this will be largely responsible for the severe 
neuropathic pain. Specifically, stem cell therapy represents a promising method for 
treating neurological deficits stemming from SCIs. However, the key questions still 
remain to be answered. In this project, the GABAergic precursors are transplanted into 
the first relay station of the pain pathway to inhibit pain transmission, using the dorsal 
spinal cord hemi-section rat model. The rats used in our study are divided into three 
subgroups, including shame operation group, transplanted with culture medium group 
and transplanted with GABAergic precursors group. Of them, the GABAergic precursor 
cells transplanted in this study are derived from the telencephalic vesicles from E12 rat 
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embryos. Moreover, the behaviors of these animals will be assessed in terms of pain 
sensitivity through applying von Frey filaments on a weekly basis. Two months later, 
the animals are sacrificed to collect their spinal cords. Then, immunohistochemical 
staining and analysis under a confocal laser microscope would be performed by my 
colleagues. The mechanical pain threshold is slightly increased after the transplantation 
and is not fully restored. The findings of this study suggest that the transplantation of 
GABAergic precursors can alleviate neuropathic pain caused by a hemi-section of the 
spinal cord.  
 
5.2. Zusammenfassung 
Rückenmarksverletzung (SCI) ist eine führende Ursache für permanente Behinderung 
und chronischen Schmerz, der bekanntermaßen Überreizbarkeit in einer Vielzahl von 
Neuronen im Hinterhorn des Rückenmarks induzieren kann. Dies wird wiederum 
weitgehend für die schweren neuropathischen Schmerzen verantwortlich sein. 
Insbesondere stellt die Stammzelltherapie eine vielversprechende Methode zur 
Behandlung von neurologischen Defiziten dar, die von SCIs herrühren. Die 
Schlüsselfragen müssen jedoch noch beantwortet werden. In diesem Projekt werden die 
GABAergen Vorläufer in die erste Relaisstation des Schmerzwegs transplantiert, um die 
Schmerzübertragung zu hemmen, wobei das dorsale Rückenmarkshemisektions  
Rattenmodell verwendet wird. Die Ratten, die in unserer Studie verwendet wurden, sind 
in drei Untergruppen unterteilt, einschließlich einer Scham-Operationsgruppe, 
transplantiert mit einer Kulturmediumgruppe und transplantiert mit einer GABAergen 
Vorläufergruppe. Von diesen sind die in dieser Studie transplantierten GABAergen 
Vorläuferzellen von den telenzephalen Vesikeln von E12-Rattenembryonen abgeleitet. 
Darüber hinaus wird das Verhalten dieser Tiere im Hinblick auf die 
Schmerzempfindlichkeit durch Anwendung von von Frey-Filamenten wöchentlich 
untersucht. Zwei Monate später werden die Tiere geopfert, um ihr Rückenmark zu 
untersuchen. Dann wurden von meiner Kollegin immunhistochemische Färbungen und 
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Analysen unter einem konfokalen Lasermikroskop durchgeführt. Die mechanische 
Schmerzschwelle ist nach der Transplantation leicht erhöht und nicht vollständig 
wiederhergestellt. Die Ergebnisse dieser Studie deuten darauf hin, dass die 
Transplantation von GABAergen Vorläufern neuropathischen Schmerz lindern kann, der 
durch eine Hemi-Section des Rückenmarks verursacht wird. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
 
 
6. List of Figures 
 
Fig.1. Dorsal horn and primary afferent inputs(Benarroch 2016). ....... 14 
Fig.2. Mechanism of Mechanical allodynia and itch. The loss of GABA, 
glycinergic or dynorphin inhibition in the dorsal horn.(Benarroch 
2016) ................................................................................................... 18 
Fig.3. Hemisection of T13 spinal cord using the No. 11 surgical blade at 
the cutting depth of 1 mm. ............................................................... 22 
Fig.4. Collection of LGE, MGE and POA tissues from the E14 rat 
embryos. ............................................................................................ 24 
Fig.5. A schematic overview of the major steps in this protocol. ........ 25 
Fig.6. Culture of NPCs. (A) First day of culture. (B) Four days of culture. 
(C) Eight days of culture (D) Twelve days of culture. All the scale 
bars were 100um. .............................................................................. 26 
Fig.7. Transplantation of cells and PBS. ................................................ 28 
Fig.8. Pain assessment electronic von Frey filaments for quantification 
of tactile sensation (thickly-myelinated fibers) (Ugo Basile, Italy) 31 
Fig.9. The BBB scores of the sham operation group. ........................... 33 
Fig.10. The BBB scores in PBS transplantation group.. ....................... 35 
Fig.11. BBB scores in cells transplantation group. ............................... 37 
Fig.12. BBB Score on the injury (dorsal hemisection) side of the 
hindlimbs. .......................................................................................... 39 
Fig.13. Mechanical pain threshold in the sham operation group. ........ 40 
Fig.14. Mechanical pain threshold in PBS transplantation group. ...... 41 
Fig.15. Mechanical pain threshold in cells transplantation group. ...... 42 
Fig.16. Changes in mechanical pain thresholds following hemisection 
of the dorsal column. ........................................................................ 43 
 
54 
 
 
 
7. List of Tables 
 
Table 1. Classification of pain after SCI (Widerstrom-Noga, 
Biering-Sorensen et al. 2014) ........................................................... 10 
Table 2. BBB locomotor rating sheet. .................................................... 29 
Table 3. BBB locomotor rating scale.(Basso, Beattie et al. 1995) ........ 30 
Table 4. Quantification of BBB Scores in sham operation group. ....... 34 
Table 5. Quantification of BBB Scores in PBS transplantation group. 36 
Table 6. Quantification of BBB Scores in cells transplantation group. 38 
Table 7. Quantification of Mechanical Behavioral Assays .................... 44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
 
 
 
8. Acknowledgements 
 
Hereby I want to thank my family for giving me support during the three years. 
Because of their accompany I always feel full of love. Each time when the 
experiment didn't go well, they all keep encourage me and give me the 
self-confidence to carry on. 
 
I also want to thank Prof. Matthias Morgalla for his supervision. He is not only a 
supervisor but also a mentor. He gave me many pieces of advice for my 
research and my life here in Germany. He is so kind and he has a warm heart. 
He never speaks harshly on us and let us feel at home. He is the kind of person 
that I want to be. 
 
I also feel grateful to my colleagues and friends. Jun Li helped me to start the 
project and Qi Zhang helped me doing the slices and staining. Yi Zhang also 
gave me many lectures about the pain.  
 
It is my pleasure to have the opportunity to do the doctor study at Hertie Institut. 
Here I learned how to do a rigorous experimental design and analysis. Tübingen 
is a beautiful city, which has a nice nature cinerary. And the university is also 
amazing. There are so many international students working as a super team and 
the multi cultures are also united together here.  
 
 
 
 
 
 
56 
 
 
 
9. Erklärung zum Eigenanteil der Dissertationsschrift 
 
Die Arbeit wurde in der Hertie Institut und Klinik für Neurochirurgie unter 
Betreuung von Prof. Dr. med. MH Morgalla durchgeführt. 
 
Die Konzeption der Studie erfolgte in Zusammenarbeit mit Prof. Dr. med. MH 
Morgalla durchgeführt. 
 
Sämtliche Versuche wurden (nach Einarbeitung durch Labormitglieder Prof. Dr. 
med. MH Morgalla von mir mit Unterstützung durch Prof. Dr. med. MH Morgalla 
durchgeführt. 
 
Die statistische Auswertung erfolgte nach Anleitung durch Prof. Dr. med. MH 
Morgalla druchgeführt. 
 
Ich versichere, das Manuskript selbständig (nach Anleitung durch Prof. Dr. med. 
MH Morgalla) verfasst zu haben und keine weiteren als die von mir 
angegebenen Quellen verwendet zu haben. 
 
 
 
 
Tübingen, den 08.08.2018 
 
 
 
 
 
 
Unterschrift 
 
 
57 
 
 
 
10. Einverständnis zur elektronischen Veröffentlichung der 
Dissertationsschrift 
 
Einverständnis des Betreuers/der Betreuerin zur elektronischen 
Veröffentlichung der Dissertationsschrift über TOBIAS-lib bei der 
Universitätsbibliothek Tübingen 
 
 
Name, Vorname des Doktoranden:   Tianci Cheng 
 
Titel der Dissertation:  GABAergic neural stem cells transplantation after 
spinal cord injury induced chronic neuropathic pain in a rat model. 
 
 
 
Name, Vorname des habilitierten Betreuers / der habilitierten Betreuerin: 
 
 
 
Ich bin mit der elektronischen Veröffentlichung der Dissertation auf dem 
Publikationsserver der Universitätsbibliothek Tübingen einverstanden. 
 
Hinweis: 
Die Publikation auf den Servern der Universität kann eine spätere anderweitige 
Veröffentlichung erschweren oder verhindern. Sollten Sie nicht mit der 
elektronischen Veröffentlichung einverstanden sein, schicken Sie bitte einen 
begründeten Antrag auf Veröffentlichung in Papierform an das Promotionsbüro 
der Fakultät. 
 
 
 
 
Datum, Unterschrift des Betreuers:    
 
 
 
 
 
 
 
 
58 
 
 
 
11. Curriculum Vitae 
Name: Tianci Cheng   geb. 28.11.1989 in Jiangsu China 
Anschrift:   Fichtenweg 9 | Zi 217-218 | 72076 Tübingen 
Universitätsstudium 
Oct 2015 - Oct 2018 Universität Tübingen （Doktor Medizin） 
September 2013 – Juli 2015 Medizinische Universität Chinas (Master) 
September 2008 – Juli 2013 Medizinische Universität Chinas (Bachelor) 
Ausbildung 
10.2013 - 03.2014/10.2014 - 06.2015 Neurochirurgie (60 Wochen) 
04.2014 - 05.2014 Allgemeine Chirurgie (8 Wochen) 
06.2014 - 07.2014 Orthopädische Chirurgie (8 Wochen) 
08.2014 – 09.2014 Radiologie (8 Wochen) 
2012 - 2013 Respiratioonsmedizin (4 Wochen) 
Gastroenterologie (4 Wochen) 
Kardiologie (4 Wochen) 
Neurologie (4 Wochen) 
Allgemeine Chirurgie (8 Wochen) 
Orthopädie (4 Wochen) 
Gynäkologie (4 Wochen) 
Pädiatrie (4 Wochen) 
Psychologie (2 Wochen) 
Primäre Gesundheitsversorgung (2 
Wochen) 
2009 - 2010 Einführung in klinische Medizin (7 
Wochen) 
Frühes Forschungstraining (8 Wochen) 
Kenntnisse & Fähigkeiten 
Fremdsprachen: Englisch IELTS 6.5; Deutsch Telc B2 
 
59 
 
 
 
 
 
 
 
12. References 
 
Altier, C. and G. W. Zamponi (2004). "Targeting Ca2+ channels to treat pain: T-type versus N-type." 
Trends Pharmacol Sci 25(9): 465-470. 
 
Amir, R. and M. Devor (1993). "Ongoing activity in neuroma afferents bearing retrograde sprouts." 
Brain Res 630(1-2): 283-288. 
 
Andresen, S. R., F. Biering-Sorensen, E. M. Hagen, J. F. Nielsen, F. W. Bach and N. B. Finnerup 
(2016). "Pain, spasticity and quality of life in individuals with traumatic spinal cord injury in 
Denmark." Spinal Cord 54(11): 973-979. 
 
Attal, N., G. Cruccu, R. Baron, M. Haanpaa, P. Hansson, T. S. Jensen, T. Nurmikko and S. European 
Federation of Neurological (2010). "EFNS guidelines on the pharmacological treatment of 
neuropathic pain: 2010 revision." Eur J Neurol 17(9): 1113-e1188. 
 
Babu, H., G. Ramirez-Rodriguez, K. Fabel, J. Bischofberger and G. Kempermann (2009). "Synaptic 
Network Activity Induces Neuronal Differentiation of Adult Hippocampal Precursor Cells through 
BDNF Signaling." Front Neurosci 3: 49. 
 
Baptiste, D. C., A. Tighe and M. G. Fehlings (2009). "Spinal cord injury and neural repair: focus on 
neuroregenerative approaches for spinal cord injury." Expert Opin Investig Drugs 18(5): 663-673. 
 
Baron, R., A. Binder and G. Wasner (2010). "Neuropathic pain: diagnosis, pathophysiological 
mechanisms, and treatment." Lancet Neurol 9(8): 807-819. 
 
Basbaum, A. I., D. M. Bautista, G. Scherrer and D. Julius (2009). "Cellular and molecular 
mechanisms of pain." Cell 139(2): 267-284. 
 
Basso, D. M., M. S. Beattie and J. C. Bresnahan (1995). "A sensitive and reliable locomotor rating 
scale for open field testing in rats." J Neurotrauma 12(1): 1-21. 
 
Benarroch, E. E. (2016). "Dorsal horn circuitry: Complexity and implications for mechanisms of 
neuropathic pain." Neurology 86(11): 1060-1069. 
 
Besse, D., M. C. Lombard and J. M. Besson (1992). "Plasticity of &mgr; and delta Opioid Receptors 
60 
 
 
 
in the Superficial Dorsal Horn of the Adult Rat Spinal Cord Following Dorsal Rhizotomies: A 
Quantitative Autoradiographic Study." Eur J Neurosci 4(10): 954-965. 
 
Bhisitkul, R. B., J. D. Kocsis, T. R. Gordon and S. G. Waxman (1990). "Trophic influence of the 
distal nerve segment on GABAA receptor expression in axotomized adult sensory neurons." Exp 
Neurol 109(3): 273-278. 
 
Blits, B., G. J. Boer and J. Verhaagen (2002). "Pharmacological, cell, and gene therapy strategies to 
promote spinal cord regeneration." Cell Transplant 11(6): 593-613. 
 
Bouhassira, D., M. Lanteri-Minet, N. Attal, B. Laurent and C. Touboul (2008). "Prevalence of 
chronic pain with neuropathic characteristics in the general population." Pain 136(3): 380-387. 
 
Bowker, R. M., K. N. Westlund and J. D. Coulter (1981). "Origins of serotonergic projections to the 
spinal cord in rat: an immunocytochemical-retrograde transport study." Brain Res 226(1-2): 187-199. 
 
Brazelton, T. R., F. M. Rossi, G. I. Keshet and H. M. Blau (2000). "From marrow to brain: 
expression of neuronal phenotypes in adult mice." Science 290(5497): 1775-1779. 
 
Cardenas, D. D. and E. R. Felix (2009). "Pain after spinal cord injury: a review of classification, 
treatment approaches, and treatment assessment." PM R 1(12): 1077-1090. 
 
Choi, D. and K. Gladwin (2015). "Olfactory ensheathing cells: Part II--source of cells and 
application to patients." World Neurosurg 83(2): 251-256. 
 
Chong, M. S. and Z. H. Bajwa (2003). "Diagnosis and treatment of neuropathic pain." J Pain 
Symptom Manage 25(5 Suppl): S4-S11. 
 
Chuquilin, M., Y. Alghalith and K. H. Fernandez (2016). "Neurocutaneous disease: Cutaneous 
neuroanatomy and mechanisms of itch and pain." J Am Acad Dermatol 74(2): 197-212. 
 
Collins, S., M. J. Sigtermans, A. Dahan, W. W. Zuurmond and R. S. Perez (2010). "NMDA receptor 
antagonists for the treatment of neuropathic pain." Pain Med 11(11): 1726-1742. 
 
Conrad, S., M. Renninger, J. Hennenlotter, T. Wiesner, L. Just, M. Bonin, W. Aicher, H. J. Buhring, 
U. Mattheus, A. Mack, H. J. Wagner, S. Minger, M. Matzkies, M. Reppel, J. Hescheler, K. D. Sievert, 
A. Stenzl and T. Skutella (2008). "Generation of pluripotent stem cells from adult human testis." 
Nature 456(7220): 344-349. 
 
Dasari, V. R., D. G. Spomar, C. S. Gondi, C. A. Sloffer, K. L. Saving, M. Gujrati, J. S. Rao and D. H. 
Dinh (2007). "Axonal remyelination by cord blood stem cells after spinal cord injury." J 
Neurotrauma 24(2): 391-410. 
61 
 
 
 
 
Dasari, V. R., K. K. Veeravalli and D. H. Dinh (2014). "Mesenchymal stem cells in the treatment of 
spinal cord injuries: A review." World J Stem Cells 6(2): 120-133. 
 
Deans, R. J. and A. B. Moseley (2000). "Mesenchymal stem cells: biology and potential clinical 
uses." Exp Hematol 28(8): 875-884. 
 
Devor, M., P. D. Wall and N. Catalan (1992). "Systemic lidocaine silences ectopic neuroma and 
DRG discharge without blocking nerve conduction." Pain 48(2): 261-268. 
 
Dhaka, A., T. J. Earley, J. Watson and A. Patapoutian (2008). "Visualizing cold spots: 
TRPM8-expressing sensory neurons and their projections." J Neurosci 28(3): 566-575. 
 
Dickenson, A. H., V. Chapman and G. M. Green (1997). "The pharmacology of excitatory and 
inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal 
cord." Gen Pharmacol 28(5): 633-638. 
 
Drew, G. M., P. J. Siddall and A. W. Duggan (2004). "Mechanical allodynia following contusion 
injury of the rat spinal cord is associated with loss of GABAergic inhibition in the dorsal horn." Pain 
109(3): 379-388. 
 
Duan, B., L. Cheng, S. Bourane, O. Britz, C. Padilla, L. Garcia-Campmany, M. Krashes, W. 
Knowlton, T. Velasquez, X. Ren, S. Ross, B. B. Lowell, Y. Wang, M. Goulding and Q. Ma (2014). 
"Identification of spinal circuits transmitting and gating mechanical pain." Cell 159(6): 1417-1432. 
 
Dworkin, R. H., A. B. O'Connor, J. Kent, S. C. Mackey, S. N. Raja, B. R. Stacey, R. M. Levy, M. 
Backonja, R. Baron, H. Harke, J. D. Loeser, R. D. Treede, D. C. Turk, C. D. Wells and G. 
International Association for the Study of Pain Neuropathic Pain Special Interest (2013). 
"Interventional management of neuropathic pain: NeuPSIG recommendations." Pain 154(11): 
2249-2261. 
 
Eftekharpour, E., S. Karimi-Abdolrezaee and M. G. Fehlings (2008). "Current status of experimental 
cell replacement approaches to spinal cord injury." Neurosurg Focus 24(3-4): E19. 
 
Eid, S. R., E. D. Crown, E. L. Moore, H. A. Liang, K. C. Choong, S. Dima, D. A. Henze, S. A. Kane 
and M. O. Urban (2008). "HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and 
neuropathy-induced mechanical hypersensitivity." Mol Pain 4: 48. 
 
Eide, P. K., E. Jorum and A. E. Stenehjem (1996). "Somatosensory findings in patients with spinal 
cord injury and central dysaesthesia pain." J Neurol Neurosurg Psychiatry 60(4): 411-415. 
 
Felsby, S., J. Nielsen, L. Arendt-Nielsen and T. S. Jensen (1996). "NMDA receptor blockade in 
62 
 
 
 
chronic neuropathic pain: a comparison of ketamine and magnesium chloride." Pain 64(2): 283-291. 
 
Field, M. J., J. Hughes and L. Singh (2000). "Further evidence for the role of the alpha(2)delta 
subunit of voltage dependent calcium channels in models of neuropathic pain." Br J Pharmacol 
131(2): 282-286. 
 
Finnerup, N. B., I. L. Johannesen, S. H. Sindrup, F. W. Bach and T. S. Jensen (2001). "Pain and 
dysesthesia in patients with spinal cord injury: A postal survey." Spinal Cord 39(5): 256-262. 
 
Fischer, L., C. H. Tambeli and C. A. Parada (2008). "TRPA1-mediated nociception." Neuroscience 
155(2): 337-338. 
 
Foster, E., H. Wildner, L. Tudeau, S. Haueter, W. T. Ralvenius, M. Jegen, H. Johannssen, L. Hosli, K. 
Haenraets, A. Ghanem, K. K. Conzelmann, M. Bosl and H. U. Zeilhofer (2015). "Targeted ablation, 
silencing, and activation establish glycinergic dorsal horn neurons as key components of a spinal 
gate for pain and itch." Neuron 85(6): 1289-1304. 
 
French, D. D., R. R. Campbell, S. Sabharwal, A. L. Nelson, P. A. Palacios and D. Gavin-Dreschnack 
(2007). "Health care costs for patients with chronic spinal cord injury in the Veterans Health 
Administration." J Spinal Cord Med 30(5): 477-481. 
 
Ge, S., E. L. Goh, K. A. Sailor, Y. Kitabatake, G. L. Ming and H. Song (2006). "GABA regulates 
synaptic integration of newly generated neurons in the adult brain." Nature 439(7076): 589-593. 
Gilron, I., R. Baron and T. Jensen (2015). "Neuropathic pain: principles of diagnosis and treatment." 
Mayo Clin Proc 90(4): 532-545. 
 
Gutierrez-Mecinas, M., A. M. Bell, A. Marin, R. Taylor, K. A. Boyle, T. Furuta, M. Watanabe, E. 
Polgar and A. J. Todd (2017). "Preprotachykinin A is expressed by a distinct population of excitatory 
neurons in the mouse superficial spinal dorsal horn including cells that respond to noxious and 
pruritic stimuli." Pain 158(3): 440-456. 
 
Gwak, Y. S. and C. E. Hulsebosch (2011). "GABA and central neuropathic pain following spinal 
cord injury." Neuropharmacology 60(5): 799-808. 
 
Gwak, Y. S., J. Kang, G. C. Unabia and C. E. Hulsebosch (2012). "Spatial and temporal activation of 
spinal glial cells: role of gliopathy in central neuropathic pain following spinal cord injury in rats." 
Exp Neurol 234(2): 362-372. 
 
Gwak, Y. S., H. Y. Tan, T. S. Nam, K. S. Paik, C. E. Hulsebosch and J. W. Leem (2006). "Activation 
of spinal GABA receptors attenuates chronic central neuropathic pain after spinal cord injury." J 
Neurotrauma 23(7): 1111-1124. 
 
63 
 
 
 
Hains, B. C., S. D. Fullwood, M. J. Eaton and C. E. Hulsebosch (2001). "Subdural engraftment of 
serotonergic neurons following spinal hemisection restores spinal serotonin, downregulates serotonin 
transporter, and increases BDNF tissue content in rat." Brain Res 913(1): 35-46. 
 
Hains, B. C., K. M. Johnson, M. J. Eaton, W. D. Willis and C. E. Hulsebosch (2003). "Serotonergic 
neural precursor cell grafts attenuate bilateral hyperexcitability of dorsal horn neurons after spinal 
hemisection in rat." Neuroscience 116(4): 1097-1110. 
 
Hains, B. C., K. M. Johnson, D. J. McAdoo, M. J. Eaton and C. E. Hulsebosch (2001). "Engraftment 
of serotonergic precursors enhances locomotor function and attenuates chronic central pain behavior 
following spinal hemisection injury in the rat." Exp Neurol 171(2): 361-378. 
 
Hains, B. C., J. P. Klein, C. Y. Saab, M. J. Craner, J. A. Black and S. G. Waxman (2003). 
"Upregulation of sodium channel Nav1.3 and functional involvement in neuronal hyperexcitability 
associated with central neuropathic pain after spinal cord injury." J Neurosci 23(26): 8881-8892. 
 
Handreck, A., B. Backofen-Wehrhahn, S. Broer, W. Loscher and M. Gernert (2014). "Anticonvulsant 
effects by bilateral and unilateral transplantation of GABA-producing cells into the subthalamic 
nucleus in an acute seizure model." Cell Transplant 23(1): 111-132. 
 
Hao, J. X., X. J. Xu and Z. Wiesenfeld-Hallin (1994). "Intrathecal gamma-aminobutyric acidB 
(GABAB) receptor antagonist CGP 35348 induces hypersensitivity to mechanical stimuli in the rat." 
Neurosci Lett 182(2): 299-302. 
 
Hendricks, W. A., E. S. Pak, J. P. Owensby, K. J. Menta, M. Glazova, J. Moretto, S. Hollis, K. L. 
Brewer and A. K. Murashov (2006). "Predifferentiated embryonic stem cells prevent chronic pain 
behaviors and restore sensory function following spinal cord injury in mice." Mol Med 12(1-3): 
34-46. 
 
Hollrigel, G. S., K. Toth and I. Soltesz (1996). "Neuroprotection by propofol in acute mechanical 
injury: role of GABAergic inhibition." J Neurophysiol 76(4): 2412-2422. 
 
Houle, J. D. and A. Tessler (2003). "Repair of chronic spinal cord injury." Exp Neurol 182(2): 
247-260. 
 
Huang, J. J., X. M. Zhang and P. A. McNaughton (2006). "Modulation of temperature-sensitive TRP 
channels." Seminars in Cell & Developmental Biology 17(6): 638-645. 
 
Hudson, L. J., S. Bevan, G. Wotherspoon, C. Gentry, A. Fox and J. Winter (2001). "VR1 protein 
expression increases in undamaged DRG neurons after partial nerve injury." Eur J Neurosci 13(11): 
2105-2114. 
 
64 
 
 
 
Ikoma, A., M. Fartasch, G. Heyer, Y. Miyachi, H. Handwerker and M. Schmelz (2004). "Painful 
stimuli evoke itch in patients with chronic pruritus: central sensitization for itch." Neurology 62(2): 
212-217. 
 
Inoue, K., M. Tsuda and S. Koizumi (2005). "ATP receptors in pain sensation: Involvement of spinal 
microglia and P2X(4) receptors." Purinergic Signal 1(2): 95-100. 
 
Ito, S., E. Okuda-Ashitaka and T. Minami (2001). "Central and peripheral roles of prostaglandins in 
pain and their interactions with novel neuropeptides nociceptin and nocistatin." Neurosci Res 41(4): 
299-332. 
 
Janssen, S. P., M. Truin, M. Van Kleef and E. A. Joosten (2011). "Differential GABAergic 
disinhibition during the development of painful peripheral neuropathy." Neuroscience 184: 183-194. 
 
Jensen, M. P., M. J. Chodroff and R. H. Dworkin (2007). "The impact of neuropathic pain on 
health-related quality of life - Review and implications." Neurology 68(15): 1178-1182. 
 
Jensen, T. S., H. Gottrup, S. H. Sindrup and F. W. Bach (2001). "The clinical picture of neuropathic 
pain." Eur J Pharmacol 429(1-3): 1-11. 
 
Jiang, X., T. W. Fuller, J. Bandari, U. Bansal, Z. Zhang, B. Shen, J. Wang, J. R. Roppolo, W. C. de 
Groat and C. Tai (2016). "Contribution of GABAA, Glycine, and Opioid Receptors to Sacral 
Neuromodulation of Bladder Overactivity in Cats." J Pharmacol Exp Ther 359(3): 436-441. 
 
Jolkkonen, J., T. Halonen, E. Jolkkonen, J. Nissinen and A. Pitkanen (1996). "Seizure-induced 
damage to the hippocampus is prevented by modulation of the GABAergic system." Neuroreport 
7(12): 2031-2035. 
 
Jones, R. C., 3rd, E. Lawson and M. Backonja (2016). "Managing Neuropathic Pain." Med Clin 
North Am 100(1): 151-167. 
 
Kadoya, K., P. Lu, K. Nguyen, C. Lee-Kubli, H. Kumamaru, L. Yao, J. Knackert, G. Poplawski, J. N. 
Dulin, H. Strobl, Y. Takashima, J. Biane, J. Conner, S. C. Zhang and M. H. Tuszynski (2016). 
"Spinal cord reconstitution with homologous neural grafts enables robust corticospinal 
regeneration." Nat Med 22(5): 479-487. 
 
Kardon, A. P., E. Polgar, J. Hachisuka, L. M. Snyder, D. Cameron, S. Savage, X. Cai, S. Karnup, C. 
R. Fan, G. M. Hemenway, C. S. Bernard, E. S. Schwartz, H. Nagase, C. Schwarzer, M. Watanabe, T. 
Furuta, T. Kaneko, H. R. Koerber, A. J. Todd and S. E. Ross (2014). "Dynorphin acts as a 
neuromodulator to inhibit itch in the dorsal horn of the spinal cord." Neuron 82(3): 573-586. 
 
Khomula, E. V., V. Y. Viatchenko-Karpinski, A. L. Borisyuk, D. E. Duzhyy, P. V. Belan and N. V. 
65 
 
 
 
Voitenko (2013). "Specific functioning of Cav3.2 T-type calcium and TRPV1 channels under 
different types of STZ-diabetic neuropathy." Biochim Biophys Acta 1832(5): 636-649. 
 
Kim, D. S., S. J. Jung, T. S. Nam, Y. H. Jeon, D. R. Lee, J. S. Lee, J. W. Leem and D. W. Kim (2010). 
"Transplantation of GABAergic neurons from ESCs attenuates tactile hypersensitivity following 
spinal cord injury." Stem Cells 28(11): 2099-2108. 
 
Kim, J., Y. W. Yoon, S. K. Hong and H. S. Na (2003). "Cold and mechanical allodynia in both 
hindpaws and tail following thoracic spinal cord hemisection in rats: time courses and their 
correlates." Neurosci Lett 343(3): 200-204. 
 
Kim, J. H., J. M. Auerbach, J. A. Rodriguez-Gomez, I. Velasco, D. Gavin, N. Lumelsky, S. H. Lee, J. 
Nguyen, R. Sanchez-Pernaute, K. Bankiewicz and R. McKay (2002). "Dopamine neurons derived 
from embryonic stem cells function in an animal model of Parkinson's disease." Nature 418(6893): 
50-56. 
 
Kobayashi, Y., Y. Okada, G. Itakura, H. Iwai, S. Nishimura, A. Yasuda, S. Nori, K. Hikishima, T. 
Konomi, K. Fujiyoshi, O. Tsuji, Y. Toyama, S. Yamanaka, M. Nakamura and H. Okano (2012). 
"Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal 
cord injury in common marmoset without tumorigenicity." PLoS One 7(12): e52787. 
 
Kwon, B. K. and W. Tetzlaff (2001). "Spinal cord regeneration: from gene to transplants." Spine 
(Phila Pa 1976) 26(24 Suppl): S13-22. 
 
Labuz, D., V. Spahn, M. O. Celik and H. Machelska (2016). "Opioids and TRPV1 in the peripheral 
control of neuropathic pain--Defining a target site in the injured nerve." Neuropharmacology 101: 
330-340. 
 
Leo, M., L. I. Schmitt, M. Erkel, M. Melnikova, J. Thomale and T. Hagenacker (2017). 
"Cisplatin-induced neuropathic pain is mediated by upregulation of N-type voltage-gated calcium 
channels in dorsal root ganglion neurons." Exp Neurol 288: 62-74. 
 
Lepski, G. (2012). "What do we know about the neurogenic potential of different stem cell types?" 
Arq Neuropsiquiatr 70(7): 540-546. 
 
Lepski, G., C. E. Jannes, B. Strauss, S. K. Marie and G. Nikkhah (2010). "Survival and neuronal 
differentiation of mesenchymal stem cells transplanted into the rodent brain are dependent upon 
microenvironment." Tissue Eng Part A 16(9): 2769-2782. 
 
Lepski, G., C. E. Jannes, J. Wessolleck, E. Kobayashi and G. Nikkhah (2011). "Equivalent 
neurogenic potential of wild-type and GFP-labeled fetal-derived neural progenitor cells before and 
after transplantation into the rodent hippocampus." Transplantation 91(4): 390-397. 
66 
 
 
 
 
Lewin, G. R. and A. Nykjaer (2014). "Pro-neurotrophins, sortilin, and nociception." Eur J Neurosci 
39(3): 363-374. 
 
Light, A. R. and E. R. Perl (1979). "Spinal termination of functionally identified primary afferent 
neurons with slowly conducting myelinated fibers." J Comp Neurol 186(2): 133-150. 
 
Liu, B. and S. E. Jordt (2018). "Cooling the Itch via TRPM8." J Invest Dermatol 138(6): 1254-1256. 
Liu, Q., S. Vrontou, F. L. Rice, M. J. Zylka, X. Dong and D. J. Anderson (2007). "Molecular genetic 
visualization of a rare subset of unmyelinated sensory neurons that may detect gentle touch." Nat 
Neurosci 10(8): 946-948. 
 
Luiz, A. P. and J. N. Wood (2016). "Sodium Channels in Pain and Cancer: New Therapeutic 
Opportunities." Adv Pharmacol 75: 153-178. 
 
Maciaczyk, J., I. Singec, D. Maciaczyk and G. Nikkhah (2008). "Combined use of BDNF, ascorbic 
acid, low oxygen, and prolonged differentiation time generates tyrosine hydroxylase-expressing 
neurons after long-term in vitro expansion of human fetal midbrain precursor cells." Exp Neurol 
213(2): 354-362. 
 
Magrinelli, F., G. Zanette and S. Tamburin (2013). "Neuropathic pain: diagnosis and treatment." 
Pract Neurol 13(5): 292-307. 
 
Marlier, L., F. Sandillon, P. Poulat, N. Rajaofetra, M. Geffard and A. Privat (1991). "Serotonergic 
innervation of the dorsal horn of rat spinal cord: light and electron microscopic 
immunocytochemical study." J Neurocytol 20(4): 310-322. 
 
McLachlan, E. M., W. Janig, M. Devor and M. Michaelis (1993). "Peripheral nerve injury triggers 
noradrenergic sprouting within dorsal root ganglia." Nature 363(6429): 543-546. 
 
Meisner, J. G., A. D. Marsh and D. R. Marsh (2010). "Loss of GABAergic interneurons in laminae 
I-III of the spinal cord dorsal horn contributes to reduced GABAergic tone and neuropathic pain 
after spinal cord injury." J Neurotrauma 27(4): 729-737. 
 
Mezey, E., S. Key, G. Vogelsang, I. Szalayova, G. D. Lange and B. Crain (2003). "Transplanted bone 
marrow generates new neurons in human brains." Proc Natl Acad Sci U S A 100(3): 1364-1369. 
 
Millan, M. J. (1999). "The induction of pain: an integrative review." Prog Neurobiol 57(1): 1-164. 
Mitchell, E. A., L. J. Gentet, J. Dempster and D. Belelli (2007). "GABAA and glycine 
receptor-mediated transmission in rat lamina II neurones: relevance to the analgesic actions of 
neuroactive steroids." J Physiol 583(Pt 3): 1021-1040. 
 
67 
 
 
 
Moore, K. A., T. Kohno, L. A. Karchewski, J. Scholz, H. Baba and C. J. Woolf (2002). "Partial 
peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal 
horn of the spinal cord." J Neurosci 22(15): 6724-6731. 
 
Mukhida, K., I. Mendez, M. McLeod, N. Kobayashi, C. Haughn, B. Milne, B. Baghbaderani, A. Sen, 
L. A. Behie and M. Hong (2007). "Spinal GABAergic transplants attenuate mechanical allodynia in 
a rat model of neuropathic pain." Stem Cells 25(11): 2874-2885. 
 
Novikova, L. N., S. Lobov, M. Wiberg and L. N. Novikov (2011). "Efficacy of olfactory ensheathing 
cells to support regeneration after spinal cord injury is influenced by method of culture preparation." 
Exp Neurol 229(1): 132-142. 
 
Nozadze, I., N. Tsiklauri, G. Gurtskaia and M. G. Tsagareli (2016). "Role of thermo TRPA1 and 
TRPV1 channels in heat, cold, and mechanical nociception of rats." Behav Pharmacol 27(1): 29-36. 
O'Connor, A. B. and R. H. Dworkin (2009). "Treatment of neuropathic pain: an overview of recent 
guidelines." Am J Med 122(10 Suppl): S22-32. 
 
Orestes, P., H. P. Osuru, W. E. McIntire, M. O. Jacus, R. Salajegheh, M. M. Jagodic, W. Choe, J. Lee, 
S. S. Lee, K. E. Rose, N. Poiro, M. R. Digruccio, K. Krishnan, D. F. Covey, J. H. Lee, P. Q. Barrett, 
V. Jevtovic-Todorovic and S. M. Todorovic (2013). "Reversal of neuropathic pain in diabetes by 
targeting glycosylation of Ca(V)3.2 T-type calcium channels." Diabetes 62(11): 3828-3838. 
 
Pinho-Ribeiro, F. A., W. A. Verri, Jr. and I. M. Chiu (2017). "Nociceptor Sensory Neuron-Immune 
Interactions in Pain and Inflammation." Trends Immunol 38(1): 5-19. 
 
Plenderleith, M. B. and P. J. Snow (1993). "The plant lectin Bandeiraea simplicifolia I-B4 identifies 
a subpopulation of small diameter primary sensory neurones which innervate the skin in the rat." 
Neurosci Lett 159(1-2): 17-20. 
 
Ploner, M., M. C. Lee, K. Wiech, U. Bingel and I. Tracey (2011). "Flexible cerebral connectivity 
patterns subserve contextual modulations of pain." Cereb Cortex 21(3): 719-726. 
 
Polgar, E., C. Durrieux, D. I. Hughes and A. J. Todd (2013). "A quantitative study of inhibitory 
interneurons in laminae I-III of the mouse spinal dorsal horn." PLoS One 8(10): e78309. 
 
Polgar, E., S. Gray, J. S. Riddell and A. J. Todd (2004). "Lack of evidence for significant neuronal 
loss in laminae I-III of the spinal dorsal horn of the rat in the chronic constriction injury model." 
Pain 111(1-2): 144-150. 
 
Puchala, E. and W. F. Windle (1977). "The possibility of structural and functional restitution after 
spinal cord injury. A review." Exp Neurol 55(1): 1-42. 
 
68 
 
 
 
Ramon-Cueto, A. and M. Nieto-Sampedro (1994). "Regeneration into the spinal cord of transected 
dorsal root axons is promoted by ensheathing glia transplants." Exp Neurol 127(2): 232-244. 
 
Rexed, B. (1952). "The cytoarchitectonic organization of the spinal cord in the cat." J Comp Neurol 
96(3): 414-495. 
 
Ritter, D. M., B. M. Zemel, T. J. Hala, M. E. O'Leary, A. C. Lepore and M. Covarrubias (2015). 
"Dysregulation of Kv3.4 channels in dorsal root ganglia following spinal cord injury." J Neurosci 
35(3): 1260-1273. 
 
Rowan, S., A. J. Todd and R. C. Spike (1993). "Evidence that neuropeptide Y is present in 
GABAergic neurons in the superficial dorsal horn of the rat spinal cord." Neuroscience 53(2): 
537-545. 
 
Sanchez-Ramos, J., S. Song, F. Cardozo-Pelaez, C. Hazzi, T. Stedeford, A. Willing, T. B. Freeman, S. 
Saporta, W. Janssen, N. Patel, D. R. Cooper and P. R. Sanberg (2000). "Adult bone marrow stromal 
cells differentiate into neural cells in vitro." Exp Neurol 164(2): 247-256. 
 
Sanchez, A., B. Niedbala and M. Feria (1995). "Modulation of neuropathic pain in rats by 
intrathecally injected serotonergic agonists." Neuroreport 6(18): 2585-2588. 
 
Seal, R. P., X. Wang, Y. Guan, S. N. Raja, C. J. Woodbury, A. I. Basbaum and R. H. Edwards (2009). 
"Injury-induced mechanical hypersensitivity requires C-low threshold mechanoreceptors." Nature 
462(7273): 651-655. 
 
Sekhon, L. H. and M. G. Fehlings (2001). "Epidemiology, demographics, and pathophysiology of 
acute spinal cord injury." Spine (Phila Pa 1976) 26(24 Suppl): S2-12. 
 
Shinoda, M., K. Kawashima, N. Ozaki, H. Asai, K. Nagamine and Y. Sugiura (2007). "P2X3 
receptor mediates heat hyperalgesia in a rat model of trigeminal neuropathic pain." J Pain 8(7): 
588-597. 
 
Siddall, P. J. and J. D. Loeser (2001). "Pain following spinal cord injury." Spinal Cord 39(2): 63-73. 
Siddall, P. J., J. M. McClelland, S. B. Rutkowski and M. J. Cousins (2003). "A longitudinal study of 
the prevalence and characteristics of pain in the first 5 years following spinal cord injury." Pain 
103(3): 249-257. 
 
Sivilotti, L. and C. J. Woolf (1994). "The contribution of GABAA and glycine receptors to central 
sensitization: disinhibition and touch-evoked allodynia in the spinal cord." J Neurophysiol 72(1): 
169-179. 
 
Sokal, D. M. and V. Chapman (2001). "Spinal GABA(B)-receptor antagonism increases nociceptive 
69 
transmission in vivo." Neuroreport 12(15): 3247-3250. 
Sommer, C. and M. Kress (2004). "Recent findings on how proinflammatory cytokines cause pain: 
peripheral mechanisms in inflammatory and neuropathic hyperalgesia." Neurosci Lett 361(1-3): 
184-187. 
Sorkin, L. S., S. Puig and D. L. Jones (1998). "Spinal bicuculline produces hypersensitivity of dorsal 
horn neurons: effects of excitatory amino acid antagonists." Pain 77(2): 181-190. 
Stormer, S., H. J. Gerner, W. Gruninger, K. Metzmacher, S. Follinger, C. Wienke, W. Aldinger, N. 
Walker, M. Zimmermann and V. Paeslack (1997). "Chronic pain/dysaesthesiae in spinal cord injury 
patients: results of a multicentre study." Spinal Cord 35(7): 446-455. 
Stubley, L. A., M. A. Martinez, S. Karmally, T. Lopez, P. Cejas and M. J. Eaton (2001). "Only early 
intervention with gamma-aminobutyric acid cell therapy is able to reverse neuropathic pain after 
partial nerve injury." J Neurotrauma 18(4): 471-477. 
Tabakow, P., G. Raisman, W. Fortuna, M. Czyz, J. Huber, D. Li, P. Szewczyk, S. Okurowski, R. 
Miedzybrodzki, B. Czapiga, B. Salomon, A. Halon, Y. Li, J. Lipiec, A. Kulczyk and W. 
Jarmundowicz (2014). "Functional regeneration of supraspinal connections in a patient with 
transected spinal cord following transplantation of bulbar olfactory ensheathing cells with peripheral 
nerve bridging." Cell Transplant 23(12): 1631-1655. 
Takahashi, K. and S. Yamanaka (2006). "Induction of pluripotent stem cells from mouse embryonic 
and adult fibroblast cultures by defined factors." Cell 126(4): 663-676. 
Tan, A. M. and S. G. Waxman (2012). "Spinal cord injury, dendritic spine remodeling, and spinal 
memory mechanisms." Exp Neurol 235(1): 142-151. 
Tatagiba, M., C. Brosamle and M. E. Schwab (1997). "Regeneration of injured axons in the adult 
mammalian central nervous system." Neurosurgery 40(3): 541-546; discussion 546-547. 
Taylor, A. M., J. C. Peleshok and A. Ribeiro-da-Silva (2009). "Distribution of 
P2X(3)-immunoreactive fibers in hairy and glabrous skin of the rat." J Comp Neurol 514(6): 
555-566. 
Todd, A. J. (2010). "Neuronal circuitry for pain processing in the dorsal horn." Nat Rev Neurosci 
11(12): 823-836. 
Todd, A. J. and A. C. Sullivan (1990). "Light microscope study of the coexistence of GABA-like and 
glycine-like immunoreactivities in the spinal cord of the rat." J Comp Neurol 296(3): 496-505. 
70 
 
 
 
Torrance, N., B. H. Smith, M. I. Bennett and A. J. Lee (2006). "The epidemiology of chronic pain of 
predominantly neuropathic origin. Results from a general population survey." J Pain 7(4): 281-289. 
 
Treede, R. D., T. S. Jensen, J. N. Campbell, G. Cruccu, J. O. Dostrovsky, J. W. Griffin, P. Hansson, R. 
Hughes, T. Nurmikko and J. Serra (2008). "Neuropathic pain: redefinition and a grading system for 
clinical and research purposes." Neurology 70(18): 1630-1635. 
 
Treede, R. D., R. A. Meyer, S. N. Raja and J. N. Campbell (1992). "Peripheral and central 
mechanisms of cutaneous hyperalgesia." Prog Neurobiol 38(4): 397-421. 
 
Tsuda, M., K. Inoue and M. W. Salter (2005). "Neuropathic pain and spinal microglia: a big problem 
from molecules in "small" glia." Trends Neurosci 28(2): 101-107. 
 
von Hehn, C. A., R. Baron and C. J. Woolf (2012). "Deconstructing the neuropathic pain phenotype 
to reveal neural mechanisms." Neuron 73(4): 638-652. 
 
Werhagen, L., C. N. Budh, C. Hultling and C. Molander (2004). "Neuropathic pain after traumatic 
spinal cord injury--relations to gender, spinal level, completeness, and age at the time of injury." 
Spinal Cord 42(12): 665-673. 
 
Westgren, N. and R. Levi (1998). "Quality of life and traumatic spinal cord injury." Arch Phys Med 
Rehabil 79(11): 1433-1439. 
 
Widerstrom-Noga, E., F. Biering-Sorensen, T. Bryce, D. D. Cardenas, N. B. Finnerup, M. P. Jensen, 
J. S. Richards and P. J. Siddall (2008). "The international spinal cord injury pain basic data set." 
Spinal Cord 46(12): 818-823. 
 
Widerstrom-Noga, E., F. Biering-Sorensen, T. N. Bryce, D. D. Cardenas, N. B. Finnerup, M. P. 
Jensen, J. S. Richards and P. J. Siddall (2014). "The International Spinal Cord Injury Pain Basic Data 
Set (version 2.0)." Spinal Cord 52(4): 282-286. 
 
Wieseler-Frank, J., S. F. Maier and L. R. Watkins (2005). "Central proinflammatory cytokines and 
pain enhancement." Neurosignals 14(4): 166-174. 
 
Willis, W. D. and K. N. Westlund (1997). "Neuroanatomy of the pain system and of the pathways 
that modulate pain." J Clin Neurophysiol 14(1): 2-31. 
 
Wood, J. N., J. P. Boorman, K. Okuse and M. D. Baker (2004). "Voltage-gated sodium channels and 
pain pathways." J Neurobiol 61(1): 55-71. 
 
Xu, G. Y., G. Li, N. Liu and L. Y. Huang (2011). "Mechanisms underlying purinergic P2X3 
receptor-mediated mechanical allodynia induced in diabetic rats." Mol Pain 7: 60. 
71 
 
 
 
 
Yalcin, I., F. Barthas and M. Barrot (2014). "Emotional consequences of neuropathic pain: insight 
from preclinical studies." Neurosci Biobehav Rev 47: 154-164. 
 
Yamamoto, S., Y. Suzuki, H. Ono, K. Kume and M. Ohsawa (2016). "N- and L-type calcium 
channels blocker cilnidipine ameliorates neuropathic pain." Eur J Pharmacol 793: 66-75. 
 
Yoo, M., I. Joung, A. M. Han, H. H. Yoon and Y. K. Kwon (2007). "Distinct effect of neurotrophins 
delivered simultaneously by an adenoviral vector on neurite outgrowth of neural precursor cells from 
different regions of the brain." J Microbiol Biotechnol 17(12): 2033-2041. 
 
 
 
